Photodynamic Therapy and Diagnostics

Chlorin e4 analogs with specific structural modifications address the need for improved photosensitizers by enhancing photosensitivity, stability, and solubility, while reducing dark toxicity, effectively supporting photodynamic therapy and antiviral therapy.

JP2024542600APending Publication Date: 2024-11-15アールエムダブリュー チョ グループ リミテッド
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024531471
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-01
Filing Date
2022-11-28
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

There is a need for photosensitizers with high singlet oxygen quantum yields, strong photosensitivity in organic and aqueous media, high fluorescence quantum yields, and improved phototoxicity, stability, solubility, and lower dark toxicity, as well as easier purification methods for photodynamic therapy applications.

Method used

Development of chlorin e4 analogs and their pharmaceutically acceptable salts, characterized by specific structural modifications such as various substituents and metal complexes, to enhance photosensitivity, stability, and solubility, while minimizing dark toxicity.

Benefits of technology

The chlorin e4 analogs demonstrate enhanced photosensitivity, stability, and solubility, offering improved photodynamic therapy efficacy with reduced dark toxicity, making them suitable for tumor treatment and antiviral therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542600000001_ABST
    Figure 2024542600000001_ABST
Patent Text Reader

Abstract

The present invention relates to chlorin e4 analogs and their pharma- ceutically acceptable salts, and compositions comprising chlorin e4 analogs and their pharma- ceutically acceptable salts. The chlorin e4 analogs and their pharma- ceutically acceptable salts are suitable for use in, for example, photodynamic therapy, cytoluminescence therapy, and photodynamic diagnosis, for the treatment or detection of tumors, or in antiviral therapy. The present invention also relates to the use of chlorin e4 analogs and their pharma- ceutically acceptable salts in the manufacture of phototherapeutic or photodiagnostic agents, and methods for, for example, photodynamic therapy, cytoluminescence therapy, and photodynamic diagnosis, for the treatment or detection of tumors, or in antiviral therapy. [Formula 1] TIFF2024542600000063.tif67159
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to chlorin e4 analogs and their pharma- ceutically acceptable salts, and compositions comprising chlorin e4 analogs and their pharma- ceutically acceptable salts. The chlorin e4 analogs and their pharma- ceutically acceptable salts are suitable for use in photodynamic therapy, cytoluminescence therapy and photodynamic diagnosis, for example, in the treatment or detection of tumors, or in antiviral therapy. The present invention also relates to the use of chlorin e4 analogs and their pharma- ceutically acceptable salts in the manufacture of phototherapeutic or photodiagnostic agents, and to methods of photodynamic therapy, cytoluminescence therapy or photodynamic diagnosis, for example, in the treatment or detection of tumors, or in antiviral therapy.

[0002] The structure of "phyllochlorin" is shown below: [ka] [Background technology]

[0003] Porphyrins and their analogues are known photosensitive compounds that can absorb photons and emit them at higher wavelengths. These unique properties have many applications, one of which is photodynamic therapy (PDT).

[0004] There are currently two generations of photosensitizers for PDT: the first generation includes heme porphyrins (blood derivatives) and the second generation is mostly chlorophyll analogues. The latter compounds are known as chlorins and bacteriochlorins.

[0005] Chlorin e4 has been shown to exhibit good photosensitizing activity. Chlorin e4 has been shown to have protective effects against indomethacin-induced gastric lesions in rats and TAA or CCl4-induced acute liver injury in mice. It was therefore suggested that chlorin e4 may be a promising new drug candidate for anti-gastroenteritis and liver injury protection. WO2009 / 040411 suggests the use of chlorin e4 zinc complex in photodynamic therapy, and WO2014 / 091241 suggests the use of chlorin e4 disodium in photodynamic therapy. [ka]

[0006] However, there is a continuing need for better photosensitizers. There is a need for compounds with high singlet oxygen quantum yields, and preferably compounds with strong photosensitizing properties in organic and aqueous media. There is also a need for compounds with high fluorescence quantum yields. In addition, there is a need for compounds and / or compositions that have higher phototoxicity, lower dark toxicity, good stability, good solubility, and / or are easily purified. Summary of the Invention

[0007] A first aspect of the present invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -R 1 -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CH2N(R 2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -Rα-[N(R5)2(R5')], -Rα-[P(R5)2(R5')], or -Rα-[R8']; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α-S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected; -R α - are each independently C1 to C 42 alkylene groups, where the alkylene group can be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group can be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group, which may optionally be substituted, and which may optionally include one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n-CH3, phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl optionally includes one or more (e.g., 1, 2, 3, 4 or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each of which is -CO2 - and phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 8optionally one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; -R 8’ -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; -R 9 is hydrogen or methyl; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation; There is provided a compound of formula (I) or a complex of formula (II), or a pharma- ceutically acceptable salt thereof.

[0008] The first aspect of the present invention also relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -R 1 -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CH2N(R 2 )2, -R 2, -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected; -R 3 and -R 4are independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected; -R α - are C1 to C 42 alkylene groups, where the alkylene group can be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group can be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R βare each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group, which may optionally be substituted, and which may optionally include one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl optionally has one or more (e.g., one, two, three, four, or five) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each of which is -CO2 - and phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 , or -X; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 8 optionally one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; -R 8’ -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; -R 9 is hydrogen or methyl; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation; There is provided a compound of formula (I) or a complex of formula (II), or a pharma- ceutically acceptable salt thereof.

[0009] A first aspect of the present invention is a compound of formula (I) or a complex of formula (II) [ka] During the ceremony, -R 1 -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CH2N(R 2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ] selected from Y; -R3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ] selected from Y; -R α - are each independently C1 to C 12 alkylene groups, where the alkylene group can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group can be optionally substituted with one or more heteroatoms O or S; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which may be or contain a cyclic group, which may optionally be substituted, and which may optionally contain one or more heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, halo, -(CH2CH2O) n -H, -(CH2CH2O) n-CH3, phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl is optionally selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 8 optionally one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; n is 1, 2, 3 or 4; Y is a counter ion; X is a halo group; M 2+ is a metal ion; providing a compound of formula (I) or a complex of formula (II), or a pharma- ceutically acceptable salt thereof.

[0010] A second aspect of the invention provides a compound of formula (I) or a complex of formula (II) according to the first aspect of the invention for use in medicine.

[0011] In one embodiment of the first or second aspect of the invention, -R 1 and -R 7Both are -CO2H, -CO2Me or -CONHR 3 -R 6 Bromo, -OH, -NH-(C1-C 12 Alkyl), -O-(C1-C 12 -O-(alkyl), -O-(CH2)2-OMe, -O-CO-CF3, -O-phenyl, -O-CH2-phenyl or -O-cyclopentyl.

[0012] In the context of this specification, a "hydrocarbyl" substituent or hydrocarbyl moiety in a substituent contains only carbon and hydrogen atoms, but does not contain any heteroatoms such as N, O, S, P or Se in its carbon skeleton, unless otherwise stated. A hydrocarbyl group / moiety may be saturated or unsaturated (including aromatic), linear or branched, or may be or contain a cyclic group, and unless otherwise stated, a cyclic group does not contain heteroatoms such as N, O, S, P or Se in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and aryl groups / moieties, and all combinations of these groups / moieties. Typically, hydrocarbyl groups are C1-C 60 Hydrocarbyl groups, more typically C1-C 40 Hydrocarbyl groups, more typically C1-C 20 More typically, the hydrocarbyl group is a C1-C 12 More typically, the hydrocarbyl group is a C1-C 10 A "hydrocarbylene" group is defined as a divalent hydrocarbyl group.

[0013] An "alkyl" substituent or alkyl moiety in a substituent can be linear (i.e., straight-chained) or branched. Examples of alkyl groups / moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, and n-pentyl groups / moieties. Unless otherwise specified, the term "alkyl" does not include "cycloalkyl". Typically, alkyl groups are C1-C 12It is an alkyl group. More typically, the alkyl group is a C1-C6 alkyl group. An "alkylene" group is defined as a divalent alkyl group.

[0014] An "alkenyl" substituent or alkenyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds. Examples of alkenyl groups / moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and 1,4-hexadienyl groups / moieties. Unless otherwise specified, the term "alkenyl" does not include "cycloalkenyl". Typically, alkenyl groups are C2-C6 12 Typically, the alkenyl group is a C2-C6 alkenyl group. An "alkenylene" group is defined as a divalent alkenyl group.

[0015] An "alkynyl" substituent or alkynyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups / moieties include ethynyl, propargyl, but-1-ynyl, and but-2-ynyl. Typically, an alkynyl group is a C2-C 12 An alkynyl group. More typically, the alkynyl group is a C2-C6 alkynyl group. An "alkynylene" group is defined similarly as a divalent alkynyl group.

[0016] A "cyclic" substituent or cyclic moiety in a substituent refers to any hydrocarbyl ring, which may be saturated or unsaturated (including aromatic) and may contain one or more heteroatoms, such as N, O, S, P, or Se, in its carbon backbone. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl, and heteroaryl groups, discussed below. Cyclic groups may be monocyclic, bicyclic (e.g., bridged, fused, or spiro), or polycyclic. Typically, cyclic groups are 3-12 membered cyclic groups, meaning that they contain 3-12 ring atoms. More typically, cyclic groups are 3-7 membered monocyclic groups, meaning that they contain 3-7 ring atoms.

[0017] A "heterocyclic" substituent or heterocyclic moiety in a substituent refers to a cyclic group or moiety that contains one or more carbon atoms and one or more (such as 1, 2, 3, or 4) heteroatoms, such as N, O, S, P, or Se, in the ring structure. Examples of heterocyclic groups include the heteroaryl groups discussed below, as well as non-aromatic heterocyclic groups such as azetidinyl, azetinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl, thietanyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, thianyl, and dioxanyl groups.

[0018] A "cycloalkyl" substituent or cycloalkyl moiety in a substituent refers to a saturated hydrocarbyl ring containing, for example, 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Unless otherwise specified, a cycloalkyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.

[0019] A "cycloalkenyl" substituent or cycloalkenyl moiety in a substituent refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon-carbon double bonds and containing, for example, 3 to 7 carbon atoms, examples of which include cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, and cyclohexa-1,3-dien-1-yl. Unless otherwise specified, a cycloalkenyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.

[0020] An "aryl" substituent or aryl moiety in a substituent refers to an aromatic hydrocarbyl ring. The term "aryl" includes monocyclic aromatic hydrocarbons and polycyclic fused ring aromatic hydrocarbons, in which all of the fused ring systems (except for ring systems that are part of or formed by any substituent) are aromatic. Examples of aryl groups / moieties include phenyl, naphthyl, anthracenyl, and phenanthrenyl. Unless otherwise specified, the term "aryl" does not include "heteroaryl".

[0021] A "heteroaryl" substituent or heteroaryl moiety in a substituent refers to an aromatic heterocyclic group or moiety. The term "heteroaryl" includes monocyclic aromatic heterocycles and polycyclic fused-ring aromatic heterocycles, in which all of the fused ring systems (except for ring systems that are part of or formed by any substituent) are aromatic. Examples of heteroaryl groups / moieties include: [ka] Here, G=O, S or NH.

[0022] For purposes of this specification, when a combination of moieties is referred to as a group, e.g., arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl, the last mentioned moiety includes the atoms of the remainder of the molecule to which the group is attached. An example of an arylalkyl group is benzyl.

[0023] For purposes of this specification, an optionally substituted group or moiety (-R β etc.), (i) each hydrogen atom is optionally replaced by halo; -CN; -NO2; -N3; ​​-R x ;-OH;-OR x ;-R y -Halo;-R y -CN;-R y -NO2;-R y -N3;-R y -R x ;-R y -OH;-R y -OR x ;-SH;-SR x ;-SOR x ;-SO2H;-SO2R x ;-SO2NH2;-SO2NHR x ;-SO2N(R x )2;-R y -SH;-R y -SR x ;-R y -SOR x ;-R y -SO2H;-R y -SO2R x ;-R y -SO2NH2;-R y -SO2NHR x ;-R y -SO2N(R x )2;-NH2;-NHR x ;-N(R x )2;-N + (R x )3;-R y -NH2;-R y -NHR x ;-R y -N(R x )2;-R y -N + (R x )3;-CHO;-COR x ;-COOH;-COOR x ;-OCOR x ;-R y -CHO;-R y -COR x ;-R y -COOH;-Ry -COOR x Or -R y -OCOR x and / or may be substituted with monovalent substituents independently selected from (ii) Any two hydrogen atoms attached to the same carbon atom are oxo (=O), =S, =NH, or =NR x and / or (iii) Any two hydrogen atoms bonded to the same or different atoms within the same optionally substituted group or moiety may be replaced by -O-, -S-, -NH-, -N(R x )-, -N + (R x )2- or -R y -, and optionally substituted with bridging substituents independently selected from Here, each -R y - is independently selected from an alkylene, alkenylene, or alkynylene group which contains 1 to 6 atoms in its backbone, one or more carbon atoms in the backbone of the alkylene, alkenylene, or alkynylene group can optionally be replaced by one or more heteroatoms N, O or S, and the alkylene, alkenylene, or alkynylene group can optionally be replaced by one or more halo and / or -R x groups; and Each-R x are independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C2-C6 cyclic groups, or any two or three -R x may form a C2-C7 cyclic group together with the nitrogen atom to which they are attached, and any -R x may be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -OH, -NH2, -CN, or oxo (=O) groups.

[0024] Typically the substituents include 1, 2, 3 or 4 substituents, more typically 1, 2 or 3 substituents, more typically 1 or 2 substituents, more typically 1 substituent.

[0025] Unless otherwise indicated, any divalent bridging substituent (e.g., -O-, -S-, -NH-, -N(R x )-, -N + (R x )2- or -R y -) must be attached only to the specified group or moiety and cannot be attached to a second group or moiety, even if that second group or moiety itself may be optionally substituted.

[0026] The term "halo" includes fluoro, chloro, bromo and iodo.

[0027] Unless otherwise stated, in the case of a group prefixed with the term "halo", such as a haloalkyl or halomethyl group, the group in question should be understood to be substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodo. Usually, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two, or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four, or five halo substituents. Similarly, unless otherwise stated, in the case of a group prefixed with a particular halo group, the group in question should be understood to be substituted with one or more of the particular halo group. For example, the term "fluoromethyl" refers to a methyl group substituted with one, two, or three fluoro groups.

[0028] Unless otherwise stated, in the case of a group that is said to be "halo-substituted", it should be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Usually, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the group that is said to be halo-substituted. For example, a halo-substituted methyl group may contain one, two or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four or five halo substituents.

[0029] Unless otherwise specified, a reference to an element is considered to be a reference to all isotopes of that element, thus, for example, unless otherwise specified, a reference to hydrogen is considered to encompass all isotopes of hydrogen, including deuterium and tritium.

[0030] Unless otherwise stated, a reference to a compound or group should be considered as a reference to all tautomers of that compound or group.

[0031] When referring to a hydrocarbyl or other group which contains one or more heteroatoms N, O, S, P or Se in its carbon skeleton, or to a carbon atom of a hydrocarbyl or other group which is substituted by an N, O, S, P or Se atom, what is intended is: [ka] has been replaced with; -CH2- is replaced by -NH-, -PH-, -O-, -S- or -Se-; -CH3 is replaced by -NH2, -PH2, -OH, -SH, or -SeH; -CH= is replaced by -N= or -P=; CH2= is replaced by NH=, PH=, O=, S= or Se=; or CH≡ is replaced by N≡ or P≡; provided that the resulting group contains at least one carbon atom. For example, methoxy, dimethylamino and aminoethyl groups are considered to be hydrocarbyl groups containing one or more heteroatoms N, O, S, P or Se in their carbon skeleton.

[0032] In the context of this specification, unless otherwise stated, x ~C y A group is defined as a group containing x to y carbon atoms. For example, a C1-C4 alkyl group is defined as an alkyl group containing 1 to 4 carbon atoms. When calculating the total number of carbon atoms in a parent group including any substituted and / or moieties, the optional substituents and moieties are not taken into account. For the avoidance of doubt, a substituted heteroatom, e.g., N, O, S, P or Se, is defined as a C x ~C y When calculating the number of carbon atoms in a group, they should be counted as carbon atoms. For example, a morpholinyl group should be considered a C6 heterocyclic group, not a C4 heterocyclic group.

[0033] Because the pi electrons of the chlorin ring are delocalized, the chlorin ring can be represented by several resonance structures. Resonance structures are different ways of depicting the same compound. Two of the resonance structures of the chlorin ring are shown immediately below: [ka]

[0034] Typically, a complex contains a central metal atom or ion, known as a coordination center, and associated molecules or ions, known as ligands. Herein, the bond between the coordination center and the ligands is represented as shown in the complex below on the left (the attraction between the anionic ligand and the central metal cation is represented by four dashed lines), but equivalently, it can be represented as shown in the complex below on the right (the attraction between the ligand molecules and the central metal atom is represented by two covalent bonds and two dashed lines): [ka]

[0035] As used herein, -[NC5H5]Y means [ka] Refers to...

[0036] In one embodiment of the first or second aspect of the invention, X is a halo group selected from fluoro, chloro, bromo or iodo. In one embodiment, X is chloro or bromo.

[0037] In one embodiment of the first or second aspect of the invention there is provided a compound of formula (I):

[0038] In one embodiment of the first or second aspect of the invention, Y is a halide (e.g., fluoride, chloride, bromide or iodide) or other inorganic anion (e.g., bisulfate, hexafluorophosphate (PF6), nitrate, perchlorate, sulfate, bisulfate or phosphate) or an organic anion (e.g., acetate, ascorbate, aspartate, benzoate, besylate (benzenesulfonate), bicarbonate, bis(trifluoromethanesulfonyl)imide (TFSI), acid tartrate, butyrate, camsylate (camphorsulfonate), carbonate, citrate, decanoate, edetate, esylate (ethanesulfonate), fumarate, galactarate, gluceptate, gluconate, glutamate, glycolate, hexanoate, β-hydroxybutyrate, 2-hydroxyethanesulfonate, and the counter anion is selected from hydroxymaleate, hydroxynaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate (methanesulfonate), methylsulfate, mucate, napsylate (naphthalene-2-sulfonate), octanoate, oleate, ornithine, pamoate, pantothenate, polygalacturonate, propanoate, propionate, salicylate, stearate, succinate, tartrate, theoclate, tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BARF), tetrakis(pentafluorophenyl)borate (F5-TPB), tetraphenylborate (TPB), tosylate (toluene-p-sulfonate), or triflate (trifluoromethanesulfonate).

[0039] In another embodiment of the first or second aspect of the invention, Y is a halide (e.g., fluoride, chloride, bromide or iodide) or other inorganic anion (e.g., bisulfate, nitrate, perchlorate, phosphate or sulfate) or an organic anion (e.g., acetate, aspartate, benzoate, besylate (benzenesulfonate), butyrate, camsylate (camphorsulfonate), citrate, esylate (ethanesulfonate), fumarate, galactarate, gluconate, glutamate, glycolate, 2-hydroxyethanesulfonate, 2-methyl-2-propane ... The counter anion is selected from sulfonate, hydroxymaleate, lactate, malate, maleate, mandelate, mesylate (methanesulfonate), napsylate (naphthalene-2-sulfonate), ornithine, pamoate, pantothenate, propanoate, salicylate, succinate, tartrate, tosylate (toluene-p-sulfonate), or triflate (trifluoromethanesulfonate). In one embodiment, Y is fluoride, chloride, bromide, or iodide. In one embodiment, Y is chloride or bromide.

[0040] In one embodiment of the first or second aspect of the invention, Z is a counter cation selected from an inorganic cation (e.g., lithium, sodium, potassium, magnesium, calcium or ammonium cation) or an organic cation (e.g., an amine cation (e.g., choline or meglumine cation) or an amino acid cation (e.g., arginine cation).

[0041] In one embodiment of the first or second aspect of the invention, M 2+ Zn 2+ , Cu 2+ , Fe 2+ , Pd 2+ Or Pt 2+ In one embodiment, M 2+ Zn 2+ It is.

[0042] In one embodiment of the first or second aspect of the invention, -R 1is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2 or -C(S)-N(R 3 In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2 is selected.

[0043] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2 or -C(S)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 -C(O)-OR 3and -R 3 is C1 to C4 alkyl (preferably methyl).

[0044] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, -R 1 is -C(O)-OR 3 or -C(O)-SR 3 Selected from -R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group. Typically, in these embodiments, -R α - is C1~C 12An alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CH2CH2- groups, all of which are optionally substituted, where m is 1, 2, 3 or 4.

[0045] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), where -R 2 or -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -Rα -S(O)2R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β or -R α -SR β , selected from -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 3’ is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R3’ ), where -R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R 3’ is C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C 12 alkylene groups, where 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1~C 12 An alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CH2CH2- groups, all of which are optionally substituted, where m is 1, 2, 3 or 4.

[0046] -R 3’ The group is another -R 3 -R bonded to the same atom as the group 3 Refers to the -R group. 3 and-R 3’ may be the same or different. Preferably, -R 3 and-R 3’ is different.

[0047] In one embodiment of the first and second aspects of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R3 )(R 3’ ), where -R 2 or -R 3 -R α -R β or -R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -R β or -R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -R β or -R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C 12 An alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), -(CH2CH2O) m - group or -(CH2CH2S) m -groups, all optionally substituted, where m is 1, 2, 3 or 4.

[0048] In any of the embodiments of the previous four paragraphs, the saccharidiyl group may be optionally substituted with, for example, a protecting group such as acetyl or a natural amino acid such as valine. An amino acid may be attached to the saccharidiyl group, for example, by forming an ester between a carboxylic acid group of the amino acid and a hydroxyl group of the saccharidiyl group.

[0049] In one embodiment of the first and second aspects of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), where -R 2 or -R 3 -R α -R β or -R β -R β is a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) -OH or -OAc groups; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -R β or -R β -R βis a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -R β or -R β -R β is a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups; -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is an unsubstituted C1 to C6 alkylene group, or an unsubstituted C1 to C4 alkylene group, or an unsubstituted C1 to C2 alkylene group.

[0050] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), -R 2 or -R 3 -R α -H or -R α -OH, -R α - is C1~C 12alkylene groups, where the alkylene group can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group can be optionally substituted with one or more heteroatoms O or S; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -H or -R α -OH, -R α - is C1~C 12 alkylene groups, which may be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be optionally substituted with one or more heteroatoms O or S; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -H or -R α -OH; -R α - is C1~C 12 alkylene groups, wherein one or more carbon atoms in the backbone of the alkylene group can be optionally replaced by one or more heteroatoms O or S; -R 3’ is H or C1-C4 alkyl (preferably methyl).

[0051] In one embodiment of the first and second aspects of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3, -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R 2 or -R β and -R β are independently halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z C1-C optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) substituents selected from -NH2 12 Alkyl or C2-C 12 alkenyl group, each -R x is independently selected from C1 to C4 alkyl; z is the side chain of a natural amino acid, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R β and -Rβ are independently halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z C1-C optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) substituents selected from -NH2 12 is an alkyl group, and each -R x is independently selected from C1 to C4 alkyl; z is the side chain of a natural amino acid, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R β ;-R β is optionally halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR zis a C1-C8 alkyl group substituted with one or more (e.g., one, two, or three) substituents independently selected from -NH2, and each -R x is independently selected from C1 to C4 alkyl; -R z is the side chain of a natural amino acid; and -R 3’ is H or C1-C4 alkyl (preferably methyl).

[0052] In one embodiment of the first and second aspects of the invention, -R 1 is -CO-(NR zz -CHR z -CO) v -N(R zz )2 and -CO-(NR zz -CHR z -CO) v -OR zz where each -R z are independently selected from the side chains of natural amino acids; zz is independently selected from hydrogen and C1-C4 alkyl (preferably methyl); v is 1, 2, 3, 4, 5, 6, 7 or 8. In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), where -R 2 or -R 3 -R β and -R β is C1~C 20alkyl groups, which may be optionally substituted with one, two, three, or four halo groups, and one, two, three, four, five, or six carbon atoms in the backbone of the alkyl group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R 3’ is H or C1-C4 alkyl (preferably methyl).

[0053] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) are selected from;-R 3’ is H or C1-C4 alkyl (preferably methyl); -R 2 or -R 3 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y. In one embodiment, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) are selected from;-R 3’ is H or C1-C4 alkyl (preferably methyl); -R 2 or -R 3 -R α -[N(R 5 )3]Y, -R α-[P(R 5 )3]Y or -R α -[R 8 ]Y; each -R 5 is independently selected from C1-C4 alkyl or phenyl, where phenyl can be optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R 8 is -[NC5H5] optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R α - is C1~C 12 alkylene groups, where one, two, three, or four carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe; and Y is a counterion, preferably a halide.

[0054] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), where -R 2 or -R 3 -R α -[P(R 5 ) 3] Y, and each -R 5 is independently selected from phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl is optionally selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n-CH3 groups, n is 1, 2, 3 or 4, Y is fluoride, chloride, bromide or iodide, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -[P(R 5 ) 3] Y; each -R 5 is independently selected from phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl is optionally selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -CH3 groups; n is 1, 2, 3, or 4; Y is fluoride, chloride, bromide, or iodide; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -[P(R 5 ) 3] Y; each -R 5 is independently selected from phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl is optionally selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -CH3 groups; n is 1, 2, 3, or 4; Y is fluoride, chloride, bromide, or iodide; -R 3’is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C 12 An alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CH2CH2- groups, all of which are optionally substituted, where m is 1, 2, 3 or 4.

[0055] In one embodiment of the first or second aspect of the invention, -R 1 -C(O)-OR 3 where -R 3 is selected from hydrogen, C1-C4 alkyl (preferably methyl), or a cation (e.g., lithium, sodium, potassium, magnesium, calcium, ammonium, an amine (e.g., choline or meglumine), or a cation of an amino acid (e.g., arginine)). In one embodiment, -R 1 is -C(O)-OR 3 where -R 3 is selected from C1-C4 alkyl (preferably methyl), or a cation (eg, lithium, sodium, potassium, magnesium, calcium, ammonium, an amine (such as choline or meglumine) or an amino acid (such as arginine) cation, etc.).

[0056] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-N(R 3 In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 ).

[0057] In one embodiment of the first or second aspect of the invention, -R 1 -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CH2N(R 2 )2 or -R 2 In one embodiment, -R 1 -CH2OR 2 , -CH2SR 2 , -CH2N(R 2 )2 or -R 2 In one embodiment, -R 1 -CH2OR 2 , -CH2SR 2 or -CHN(R 2 In one embodiment, -R 1 -CH2OR 2 or -CH2SR 2 In one embodiment, -R 1 -CH2OR 2 In one embodiment, -R 1 -R 2 , and -R 2 -R α -X.

[0058] In one embodiment of the first or second aspect of the invention, -R 2 -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2Rβ , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α In one embodiment, -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, -R 2 is R α -OR β or -R α -SR β In one embodiment, -R 2 -R α -OR β or -R α -SR β , selected from -R β is a saccharidiyl group.

[0059] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR4 , -C(S)-SR 4 or -C(S)-N(R 4 In one embodiment, -R 2 is C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2 or -C(S)-N(R 4 In one embodiment, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 or -C(O)-N(R 4 )2 is selected.

[0060] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)-N(R 4 )(R 4’ ), where -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 4’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 2 is -C(O)-N(R 4 )(R 4’ ), where -R 4 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R 4’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 2 is -C(O)-N(R 4 )(R 4’), where -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 4’ is C1-C4 alkyl (preferably methyl). In one embodiment, -R 2 is -C(O)-N(R 4 )(R 4’ ), where -R 4 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R 4’ is C1 to C4 alkyl (preferably methyl).

[0061] -R 4’ The group is another -R 4 -R bonded to the same atom as the group 4 Refers to the -R group. 4 and -R 4’ may be the same or different. Preferably, -R 4 and -R 4’ are different.

[0062] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)-N(R 4 In one embodiment, -R 2 is -C(O)-N(C1-C4 alkyl)(R 4 In one embodiment, -R 2 is -C(O)-N(CH3)(R 4 ).

[0063] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R2 )2, -SR 2 , -S(O)R 2 or -S(O)2R 2 In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 In one embodiment, -R 6 -OR 2 or -SR 2 In one embodiment, -R 6 -OR 2 It is.

[0064] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 or -S(O)2R 2 , selected from -R 2 -H, -C(O)R 4 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α In one embodiment, -R6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 , selected from -R 2 -H, -C(O)R 4 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 -H, -C(O)R 4 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -Rα -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y.

[0065] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl); -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β and optionally -R β is a saccharidiyl group. In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β , optionally selected from -R β is a saccharidiyl group. In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2or -S(O)2R 2 , selected from -R 2 -R α -OR β or -R α -SR β , optionally selected from -R β is a saccharidiyl group. In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β , optionally selected from -R β is a saccharidiyl group. In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β or -R α -SR β , optionally selected from -R β is a saccharidiyl group.

[0066] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl); -R 2 is -C(O)R 4 In one embodiment, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl); -R 2 is C(O)R 4 ;-R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β Selected from;-R β is a saccharidiyl group. In one embodiment, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl); -R 2 is -C(O)R 4 ;-R 4 -R α -OR β or -R α -SR β Selected from;-R β is a saccharidiyl group.

[0067] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 , selected from -R 2 is -C(O)R 4 In one embodiment, -R 6 -OR 2 , -SR 2, -S(O)R 2 or -S(O)2R 2 -R 2 is -C(O)R 4 , and -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, -R 6 -OR 2 , -SR 2 , -S(O)R 2 or -S(O)2R 2 -R 2 is -C(O)R 4 and -R 4 -R α -OR β or -R α -SR β , selected from -R β is a saccharidiyl group.

[0068] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 or -SR 2 , selected from -R 2 is -C(O)R 4 In one embodiment, -R 6 -OR 2 or -SR 2 , and -R 2 is -C(O)R 4 and -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β , selected from -R βis a saccharidiyl group. In one embodiment, -R 6 -OR 2 or -SR 2 -R 2 is -C(O)R 4 and -R 4 -R α -OR β or -R α -SR β -R β is a saccharidiyl group.

[0069] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl); -R 2 -R β , -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β Selected from;-R β is a saccharidiyl group; -R α - is C1~C 12 In one embodiment, the -R is selected from the group consisting of an alkylene group, where one, two, three, or four carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe. 6 -OR 2 , -N(R 2 )(R 2’ ) or -SR 2 Selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl (preferably hydrogen or methyl); -R2 -R β , -R α -OR β or -R α -SR β Selected from;-R β is a saccharidiyl group; -R α - is C1~C 12 Selected from an alkylene group, one, two, three, or four carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe.

[0070] In any of the embodiments of the preceding five paragraphs, the saccharidiyl group may be optionally substituted, for example, with a protecting group such as acetyl or a natural amino acid such as valine. An amino acid may be attached to the saccharidiyl group, for example, by forming an ester between a carboxylic acid group of the amino acid and a hydroxyl group of the saccharidiyl group.

[0071] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen, C1-C4 alkyl, or -CO2(C1-C4 alkyl); -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-N(R 4 )(R 4’ ), -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y is selected from;-R 4’ is selected from hydrogen or C1-C4 alkyl; -R 4 -R α-[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 8 ]Y. In one embodiment, -R 6 -OR 2 , -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen, C1-C4 alkyl, or -CO2(C1-C4 alkyl); -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-N(R 4 )(R 4’ ), -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y is selected from;-R 4’ is selected from hydrogen or C1-C4 alkyl; -R 4 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y; each -R 5 is independently selected from C1-C4 alkyl or phenyl, where phenyl is optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R 8 is -[NC5H5] optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R α - is C1~C 12In one embodiment, -R is selected from alkylene groups, where one, two, three, or four carbon atoms in the backbone of the alkylene group may be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe; and Y is a counterion (preferably a halide). 6 -OR 2 or -N(R 2 )(R 2’ ) are selected from;-R 2’ is selected from hydrogen, C1-C4 alkyl, or -CO2(C1-C4 alkyl); -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-N(R 4 )(R 4’ ), -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y is selected from;-R 4’ is selected from hydrogen or C1-C4 alkyl; -R 4 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y; each -R 5 is independently selected from C1-C4 alkyl or phenyl, where phenyl is optionally substituted with one, two or three C1-C4 alkyl or C1-C4 alkoxy groups; -R 8 is -[NC5H5] optionally substituted with one, two, or three C1-C4 alkyl or C1-C4 alkoxy groups; -R α - is C1~C 12 alkylene groups, where 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe; and Y is a counterion (preferably a halide).

[0072] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2 is selected from hydrogen, C1-C4 alkyl, -CO(C1-C4 alkyl) or -CO2(C1-C4 alkyl). 6 -OR 2 or -N(R 2 )2 is selected;-R 2 is selected from hydrogen, C1-C4 alkyl, -CO(C1-C4 alkyl) or -CO2(C1-C4 alkyl).

[0073] In one embodiment of the first or second aspect of the invention, -R 6 -OR 2 , -N(R 2 )2, -N(R 2 )(R 2’ ), -SR 2 , -S(O)R 2 or -S(O)2R 2 Selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl; -R 2 -R 4 , -C(O)R 4 , -C(O)-OR 4 or -C(O)-N(R 4 )(R 4’ ) are selected from;-R 4’ is selected from hydrogen or C1-C4 alkyl; -R 4 is C1~C 12 In one embodiment, the -R is selected from alkyl groups, where the alkyl group may be optionally substituted with one, two, three, or four halo groups, and where one, two, three, or four carbon atoms in the backbone of the alkyl group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe. 6 -OR 2 or -N(R 2)(R 2’ ) are selected from;-R 2’ is selected from hydrogen or C1-C4 alkyl; -R 2 -R 4 , -C(O)R 4 , -C(O)-OR 4 or -C(O)-N(R 4 )(R 4’ ) are selected from;-R 4’ is selected from hydrogen or C1-C4 alkyl; -R 4 is C1~C 12 and wherein the alkyl group is optionally substituted with one, two, three, or four halo groups, and wherein one, two, three, or four carbon atoms in the backbone of the alkyl group are optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe.

[0074] In the first or second aspect of the present invention, -R 9 is hydrogen or methyl. In one embodiment, -R 9 is methyl. In a preferred embodiment, -R 9 is hydrogen.

[0075] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2, each of which is selected from -R 3 is C1-C4 alkyl, preferably each -R 3 is methyl. In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl, preferably each -R 3 is methyl. In one embodiment, -R7 is -C(O)-OR 3 , and -R 3 is C1-C4 alkyl, preferably -R 3 is methyl.

[0076] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 where -R 3 is selected from hydrogen, C1-C4 alkyl (preferably methyl) or a cation (e.g., lithium, sodium, potassium, magnesium, calcium, ammonium, the cation of an amine (e.g., choline or meglumine), or an amino acid (e.g., arginine)).

[0077] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R β ;-R β is C1-C 20 alkyl groups, where the alkyl group may be optionally substituted with one, two, three, or four halo groups, and where one, two, three, four, five, or six carbon atoms in the backbone of the alkyl group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R 3’ is H or C1-C4 alkyl (preferably methyl).

[0078] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3, -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 ) 2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β , selected from -R β is a saccharidiyl group. In one embodiment, -R 7 is -C(O)-OR 3 or -C(O)-SR 3 -R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group. Typically in these embodiments, -R α - is C1~C 12 alkylene groups, where 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1~C 12Alkylene group (preferably C1-C8 alkylene group or C1-C6 alkylene group), -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a -CH2CH2- group, all optionally substituted, where m is 1, 2, 3 or 4.

[0079] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR3 or -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β or -R α -SR β , selected from -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically in these embodiments, -R α - is C1~C 12 alkylene groups, where 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1~C 12 Alkylene group (preferably C1-C8 alkylene group or C1-C6 alkylene group), -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m is a -CH2CH2- group, all of which are optionally substituted, and m is 1, 2, 3 or 4.

[0080] -R 3’ The group is another -R 3 -R bonded to the same atom as the group 3 Refers to the -R group. 3 and -R 3’ may be the same or different. Preferably, -R 3 and -R 3’ are different.

[0081] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-N(R 3 In one embodiment, -R 7 is -C(O)-N(C1-C4 alkyl)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 7is -C(O)-N(CH3)(R 3 ) or -C(O)-NHR 3 It is.

[0082] In one embodiment of the first or second aspect of the invention, each -R α - is independent, C1~C 12 Alkylene group, -(CH2CH2O) m - group, -(CH2CH2S) m - group, -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CHCH- groups, all optionally substituted, where m is 1, 2, 3, or 4. In one embodiment, each -R α - is independent, C1~C 12 Alkylene group, -(CH2CH2O) m - group or -(CH2CH2S) m - groups, all of which are optionally substituted, where m is 1, 2, 3, or 4. In one embodiment, each -R α - is independent, C1~C 12 Alkylene group or -(CH2CH2O) m - groups, both of which are optionally substituted, where m is 1, 2, 3, or 4. In one embodiment, each -R α - is independently an optionally substituted -(CH2CH2O) m - group, where m is 1, 2, 3 or 4.

[0083] In one embodiment of the first or second aspect of the invention, each -R α - is independently a C1-C8 alkylene group, or a C1-C6 alkylene group, or a C2-C4 alkylene group, all optionally substituted.

[0084] In one embodiment of the first or second aspect of the invention, each -R α - is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl.α - is independently unsubstituted or substituted with 1 or 2 substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. α - is unsubstituted.

[0085] In one embodiment of the first or second aspect of the invention, each -R β are independently saturated or unsaturated hydrocarbyl groups which may be linear or branched or which may be or contain cyclic groups, which may optionally be substituted, and which may optionally contain one or more heteroatoms N, O or S in its carbon backbone.

[0086] In one embodiment of the first or second aspect of the invention, at least one -R β is independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all of which are optionally substituted. β is independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all optionally substituted.

[0087] In one embodiment of the first or second aspect of the invention, at least one -R β is independently a saccharidiyl group. In one embodiment, each -R β are independently a saccharidiyl group.

[0088] In one embodiment of the first or second aspect of the invention, each -R β is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. β is independently unsubstituted or substituted with 1 or 2 substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. βis non-substitutive.

[0089] In one embodiment of the first or second aspect of the invention, each -R 3 are independent of each other, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 3 are independent of each other, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, each -R 3 are independent of each other, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, each -R 3 are independent of each other, -R α -OR β or -Rα -SR β In one embodiment, each -R 3 is independently -R α -OR β or -R α -SR β -R β is a saccharidiyl group.

[0090] In one embodiment of the first or second aspect of the invention, each -R 4 is independently -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 4 is independently -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, each -R 4 is independently -R α -OR β , -R α -SR β , -R α -S(O)Rβ or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, each -R 4 is independently -R α -OR β or -R α -SR β In one embodiment, each -R 4 is independently -R α -OR β or -R α -SR β and -R β is a saccharidiyl group.

[0091] In one embodiment of the first or second aspect of the invention, -R 2 , -R 3 or -R 4 At least one of the following is independently -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidiyl group. In one embodiment, -R 2 , -R 3 or -R 4 At least one of the following is independently -R α -OR β or -R α -SR β -R β is a saccharidiyl group.

[0092] For the purposes of the present invention, a "saccharidiyl group" is any group that comprises at least one monosaccharide subunit, each of which may be optionally substituted and / or modified. Typically, a saccharidiyl group is composed of one or more monosaccharide subunits, each of which may be optionally substituted and / or modified.

[0093] Usually, a carbon atom of a single monosaccharide subunit of each saccharidiyl group is directly attached to the remainder of the compound, most typically via a single bond.

[0094] For purposes of this specification, when a first atom or group is said to be "directly bonded" to a second atom or group, it is to be understood that the first atom or group is covalently bonded to the second atom or group and that there are no intervening atom(s) or group(s). For example, in the group -(C=O)N(CH3)2, the carbon atoms of each methyl group are directly bonded to the nitrogen atom and the carbonyl group is directly bonded to the nitrogen atom, but the carbonyl group is not directly bonded to either methyl group's carbon atom.

[0095] Typically, each saccharidiyl group is derived from the corresponding saccharide by replacing a hydroxyl group of the saccharide with a group defined by the remainder of the compound.

[0096] The single bond between the anomeric carbon of a monosaccharide subunit and a substituent is called a glycosidic bond. A glycosidic group is attached to the anomeric carbon of a monosaccharide subunit by a glycosidic bond. The bond between the saccharidiyl group and the rest of the compound can be a glycosidic bond or a non-glycosidic bond. Usually, the bond between the saccharidiyl group and the rest of the compound is a glycosidic bond and the saccharidiyl group is a glycosyl group. When the bond between the saccharidiyl group and the rest of the compound is a glycosidic bond, the glycosidic bond can be in the α or β configuration. Usually, such glycosidic bonds are in the β configuration.

[0097] For the purposes of the present invention, when a saccharidiyl group "contains x monosaccharide subunits," this means that the saccharidiyl group has x monosaccharide subunits and no more. In contrast, when a saccharidiyl group "comprises x monosaccharide subunits," this means that the saccharidiyl group has x or more monosaccharide subunits.

[0098] Each saccharidiyl group may be independently selected from a monosaccharidiyl, disaccharidiyl, oligosaccharidiyl or polysaccharidiyl group. As will be appreciated, a monosaccharidiyl group contains a single monosaccharide subunit. Similarly, a disaccharidiyl group contains two monosaccharide subunits. As used herein, an "oligosaccharidiyl group" contains 2-9 monosaccharide subunits. Examples of oligosaccharidiyl groups include trisaccharidiyl, tetrasaccharidiyl, pentasaccharidiyl, hexasaccharidiyl, heptasaccharidiyl, octasaccharidiyl and nonasaccharidiyl groups. As used herein, a "polysaccharidiyl group" contains 10 or more monosaccharide subunits (such as 10-50, or 10-30, or 10-20, or 10-15 monosaccharide subunits).

[0099] Each monosaccharide subunit in a disaccharidediyl, oligosaccharidediyl or polysaccharidediyl group may be the same or different. Each monosaccharide subunit in a disaccharidediyl, oligosaccharidediyl or polysaccharidediyl group may be linked to another monosaccharide subunit in the group via a glycosidic or non-glycosidic bond. Typically, each monosaccharide subunit in a disaccharidediyl, oligosaccharidediyl or polysaccharidediyl group is linked to another monosaccharide subunit in the group via a glycosidic bond, which may be in an α or β configuration.

[0100] Each oligosaccharidiyl or polysaccharidiyl group may be a linear, branched or macrocyclic oligosaccharidiyl or polysaccharidiyl group. Typically, each oligosaccharidiyl or polysaccharidiyl group is a linear or branched oligosaccharidiyl or polysaccharidiyl group.

[0101] In one embodiment, at least one -R β is a monosaccharidiyl group or a disaccharidiyl group.

[0102] In a further embodiment, at least one -Rβ is a monosaccharide diyl group. For example, at least one -R β can be a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted. More typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit is unsubstituted.

[0103] In one embodiment, at least one -R β is an aldosyl group, where the aldosyl group can be optionally substituted and / or modified. For example, at least one -R β may be selected from a glycerosyl, aldotetrosyl (such as erythrosyl or threosyl), aldopentosyl (such as ribosyl, arabinosyl, xylosyl or lyxosyl) or aldohexosyl (such as allosyl, altrosyl, glucosyl, mannosyl, gulosyl, idosyl, galactosyl or talosyl) group, any of which may be optionally substituted and / or modified.

[0104] In another embodiment, at least one -R β is a ketosyl group, where the ketosyl group can be optionally substituted and / or modified. For example, at least one -R β may be selected from an erythrulosyl, ketopentosyl (such as ribulosyl or xylulosyl) or ketohexosyl (such as psicosyl, fructosyl, sorbosyl or tagatosyl) group, any of which may be optionally substituted and / or modified.

[0105] Each monosaccharide subunit can exist in a closed (cyclic) or open (acyclic) form. Typically, at least one -R β Each monosaccharide subunit in is present in a closed (cyclic) form. For example, at least one -R βcan be a glycosyl group containing a single closed ring monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, in such a scenario, at least one -R β is a pyranosyl or furanosyl group, such as an aldopyranosyl, aldofuranosyl, ketopyranosyl or ketofuranosyl group, any of which may be optionally substituted and / or modified. More typically, at least one -R β is a pyranosyl group, such as an aldopyranosyl or ketopyranosyl group, either of which can be optionally substituted and / or modified.

[0106] In one embodiment, at least one -R β is selected from a ribopyranosyl, arabinopyranosyl, xylopyranosyl, lyxopyranosyl, allopyranosyl, altropyranosyl, glucopyranosyl, mannopyranosyl, gulopyranosyl, idopyranosyl, galactopyranosyl or talopyranosyl group, any of which may be optionally substituted and / or modified.

[0107] In a further embodiment, at least one -R β is a glucosyl group, such as a glucopyranosyl group, where the glucosyl or glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a glucosyl group, where the glucosyl group can be optionally substituted. More typically, at least one -R β is an unsubstituted glucosyl group.

[0108] Each monosaccharide subunit may be present in the D or L configuration. Typically, each monosaccharide subunit is present in the configuration most commonly found in nature.

[0109] In one embodiment, at least one -R βis a D-glucosyl group, such as a D-glucopyranosyl group, where the D-glucosyl or D-glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a D-glucosyl group, which may be optionally substituted. More typically, at least one -R β is an unsubstituted D-glucosyl group.

[0110] For the purposes of the present invention, in the substituted monosaccharide diyl group or monosaccharide subunit: (a) one or more hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit may each independently be -H, -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -R a -OR b , -R a -SR b , -SO-R b , -SO2-R b , -SO2-OR b , -O-SO-R b , -O-SO2-R b , -O-SO2-OR b , -NR b -SO-R b , -NR b -SO2-R b , -NR b -SO2-OR b , -R a -SO-R b , -R a -SO2-R b , -R a -SO2-OR b , -SO-N(R b )2, -SO2-N(R b )2, -O-SO-N(R b )2, -O-SO2-N(R b )2, -NR b -SO-N(R b)2, -NR b -SO2-N(R b )2, -R a -SO-N(R b )2, -R a -SO2-N(R b )2, -N(R b )2, -N(R b )3 + , -R a -N(R b )2, -R a -N(R b )3 + , -P(R b )2, -PO(R b )2, -OP(R b )2, -OPO(R b )2, -R a -P(R b )2, -R a -PO(R b )2, -OSi(R b )3, -R a -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b ) 2; and / or (b) one, two, or three hydrogen atoms directly attached to a carbon atom of a monosaccharide diyl group or monosaccharide subunit are each independently -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -OH, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b、-O-R b 、-S-R b 、-R a -O-R b 、-R a -S-R b 、-SO-R b 、-SO2-R b 、-SO2-OR b 、-O-SO-R b 、-O-SO2-R b 、-O-SO2-OR b 、-NR b -SO-R b 、-NR b -SO2-R b 、-NR b -SO2-OR b 、-R a -SO-R b 、-R a -SO2-R b 、-R a -SO2-OR b 、-SO-N(R b )2、-SO2-N(R b )2、-O-SO-N(R b )2、-O-SO2-N(R b )2、-NR b -SO-N(R b )2、-NR b -SO2-N(R b )2、-R a -SO-N(R b )2、-R a -SO2-N(R b )2、-N(R b )2、-N(R b )3 + 、-R a -N(R b )2、-R a -N(R b )3 + 、-P(R b )2、-PO(R b )2、-OP(R b )2、-OPO(R b )2、-R a -P(R b )2、-R a -PO(R b )2、-OSi(Rb )3, -R a -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b ) 2; and / or (c) one or more hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit, together with a hydrogen bonded to the same carbon atom as the hydroxyl group, can each independently be represented by =O, =S, =NR b , or =N(R b )2 + and / or (d) any two hydroxyl groups of a monosaccharide diyl group or a monosaccharide subunit, taken together, are -OR c -, -SR c -,-SO-R c -,-SO2-R c -, or -NR b -R c - is replaced by; Where: Each-R a - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group which optionally contains one or more heteroatoms each independently selected from O, N and S in its carbon skeleton and preferably contains 1 to 10 carbon atoms; Each-R b- is independently hydrogen or a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group optionally containing one or more heteroatoms, each independently selected from O, N and S, in its carbon skeleton and preferably containing 1 to 15 carbon atoms; Each-R c - is independently a chemical bond, or a substituted or unsubstituted alkylene, alkenylene, or alkynylene group, optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton, and preferably containing 1 to 10 carbon atoms; However, the monosaccharide diyl group or monosaccharide subunit has at least one, preferably at least two or at least three, -OH, -OR b , -O-SO-R b , -O-SO2-R b , -O-SO2-OR b , -O-SO-N(R b )2, -O-SO2-N(R b )2, -OP(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to the condition.

[0111] Typically, in the substituted monosaccharide diyl group or monosaccharide subunit, (a) one or more hydroxyl groups of a monosaccharide diyl group or monosaccharide subunit are each independently -H, -F, -CF3, -SH, -NH2, -N3, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(Rb )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b ) 2; and / or (b) one or two of the hydrogen atoms directly attached to a carbon atom of a monosaccharide diyl group or a monosaccharide subunit are each independently -F, -CF3, -OH, -SH, -NH2, -N3, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b ) 2; and / or (c) one hydroxyl group of the monosaccharide diyl group or monosaccharide subunit is replaced with =O, with the hydrogen bonded to the same carbon atom as the hydroxyl group; and / or (d) any two hydroxyl groups of a monosaccharide diyl group or a monosaccharide subunit, taken together, are -OR c -, -NR b -R c - is replaced by; Where: Each-R b- is independently hydrogen or a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing in its carbon skeleton one, two or three heteroatoms, each independently selected from O and N, and containing one to eight carbon atoms; Each-R c - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group optionally containing in its carbon skeleton one, two or three heteroatoms each independently selected from O and N and containing 1 to 8 carbon atoms; However, the monosaccharide diyl group or monosaccharide subunit has at least two, preferably at least three, -OH, -OR b , -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to the condition.

[0112] In one embodiment, -R β is a saccharidiyl group, and one or more hydroxyl groups of the saccharidiyl group are each independently -O-CO-R b Each -R b is independently C1-C4 alkyl, preferably methyl. β is a saccharidiyl group, and all hydroxyl groups of the saccharidiyl group are each independently -O-CO-R b Each -R b are independently C1 to C4 alkyl, preferably methyl.

[0113] In the modified monosaccharide subunits, (a) the ring of the modified monosaccharidiyl group or monosaccharide subunit, or what would be the ring in the closed form of the modified monosaccharidiyl group or monosaccharide subunit, is partially unsaturated; and / or (b) The ring oxygen of the modified monosaccharide diyl group or monosaccharide subunit, or the ring oxygen of the closed ring form of the modified monosaccharide diyl group or monosaccharide subunit, is -S- or -NR d -, where each -R d - is independently hydrogen or a substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing one or more heteroatoms, each independently selected from O, N and S, in its carbon skeleton and preferably containing 1 to 15 carbon atoms.

[0114] Alternatively, when the modified monosaccharide subunit forms part of a disaccharidediyl, oligosaccharidediyl or polysaccharidediyl group, -R d may be a further monosaccharide subunit or subunits forming part of a disaccharidediyl, oligosaccharidediyl or polysaccharidediyl group, and such further monosaccharide subunit or subunits may optionally be substituted and / or modified.

[0115] Typically, in the modified monosaccharide subunits, (a) the ring of the modified monosaccharidiyl group or monosaccharide subunit, or what would be the ring in the closed form of the modified monosaccharidiyl group or monosaccharide subunit, contains a single C=C; and / or (b) The ring oxygen of the modified monosaccharide diyl group or monosaccharide subunit, or the ring oxygen of the closed ring form of the modified monosaccharide diyl group or monosaccharide subunit, is -NR d -, where each -R d- is independently hydrogen or a substituted or unsubstituted straight chain, branched or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing in its carbon skeleton one, two or three heteroatoms each independently selected from O and N, and containing one to eight carbon atoms.

[0116] Representative examples of substituted and / or modified monosaccharide subunits include those corresponding to the following: (i) deoxysugars, such as deoxyribose, fucose, fuculos and rhamnose, in which the monosaccharide diyl group or the hydroxyl group of the monosaccharide subunit is replaced by -H; (ii) amino sugars, such as glucosamine and galactosamine, in which the monosaccharide diyl group or the hydroxyl group of the monosaccharide subunit is replaced with -NH, most typically at the 2-position; and (iii) Sugar acids containing a -COOH group, such as aldonic acids (e.g. gluconic acid), urosonic acid, uronic acids (e.g. glucuronic acid) and aldaric acids (e.g. gularic or galactaric acid).

[0117] In one embodiment of the first or second aspect of the invention, at least one -R β teeth, [ka] is a monosaccharidiyl group selected from

[0118] Preferably, in the compound or complex according to the first or second aspect of the invention, at least one -R β teeth, [ka] It is.

[0119] In one embodiment of the first or second aspect of the invention, -R 2 , -R3 or -R 4 At least one of the following is independently -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β (Preferably -R α -OR β or -R α -SR β ), -R β teeth, [ka] Selected from TIFF2024542600000015.tif56159.

[0120] In one embodiment of the first or second aspect of the invention, -R 2 , -R 3 or -R 4 At least one of the following is independently -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ In one embodiment, -R 2 , -R 3 or -R 4 At least one of the following is independently -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y. In one embodiment, -R 2 , -R 3 or -R4 At least one of the following is independently [ka] is selected from.

[0121] In the first or second aspect of the present invention, each -R 5 may be the same or different. In a preferred embodiment, each -R 5 are identical.

[0122] In one embodiment of the first or second aspect of the invention, each -R 5 is independently unsubstituted or substituted with one or two substituents. In one embodiment, each -R 5 is non-substitutive.

[0123] In one embodiment of the first or second aspect of the invention, each -R 8 is independently unsubstituted or substituted with one or two substituents. In one embodiment, -R 8 is non-substitutive.

[0124] In one embodiment, -R 8 is not substituted with a halo group at the 4-position of the pyridine ring. 8 is not substituted at the 4-position of the pyridine ring. 8 is non-substitutive.

[0125] In one embodiment of the first or second aspect of the invention, -R 1 , -R 6 and -R 7 each independently contains 1 to 100 atoms other than hydrogen, preferably 1 to 80 atoms other than hydrogen, preferably 1 to 60 atoms other than hydrogen, preferably 1 to 50 atoms other than hydrogen, and preferably 1 to 45 atoms other than hydrogen.

[0126] In a particularly preferred embodiment, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -R 1 teeth: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2(-R 3 are each independently -R β and -R β is a C1 to C4 alkyl group, and more preferably, -R 1 is -C(O)-OR 3 and -R 3 -R β and -R β is a C1-C4 alkyl group; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ )(-R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl; -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β or -R α -SR β -R β is a saccharidiyl group; -R 7 teeth: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2(-R 3are each independently C1 to C4 alkyl, preferably -R 7 is -C(O)-OR 3 and -R 3 is C1-C4 alkyl); or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ )(in the formula, -R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl; -R α - is C1~C 12 alkylene groups, where the alkylene group can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group can be optionally substituted with one or more heteroatoms O or S; -R 9 is hydrogen or methyl (preferably -R 9 is hydrogen); M 2+ is a metal cation, A compound or complex, or a pharma- ceutically acceptable salt thereof, is provided.

[0127] In a particularly preferred embodiment, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, selected from -R 3are each independently -R β and -R β is a C1 to C4 alkyl group, and more preferably, -R 1 is -C(O)-OR 3 and R 3 -R β and -R β is a C1-C4 alkyl group; -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β or -R α -SR β , selected from -R β is a saccharidiyl group; -R 7 teeth: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2(-R 3 are each independently C1 to C4 alkyl, preferably -R 7 is -C(O)-OR 3 and -R 3 is C1-C4 alkyl); or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ )(in the formula, -R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R 3’ is H or C1-C4 alkyl; -R α - is C1~C 12alkylene groups, where the alkylene group can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group can be optionally substituted with one or more heteroatoms O or S; -R 9 is hydrogen or methyl (preferably -R 9 is hydrogen); M 2+ is a metal cation A compound or complex or a pharma- ceutically acceptable salt thereof is provided.

[0128] In a particularly preferred embodiment, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -R 1 teeth: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2(-R 3 are each independently -R β and -R β is a C1 to C4 alkyl group, and more preferably, -R 1 is -C(O)-OR 3 and -R 3 -R β and -R β is a C1-C4 alkyl group; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ )(-R 3 -R α -OR β or -R α -SR β -R β is a saccharidiyl group, -R3’ is H or C1-C4 alkyl; -R 6 -OR 2 or -SR 2 -R 2 -R α -OR β or -R α -SR β -R β is a saccharidiyl group; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, -R 3 are each independently C1 to C4 alkyl, preferably -R 7 is -C(O)-OR 3 and -R 3 is C1-C4 alkyl; -R α - is C1~C 12 alkylene groups, where the alkylene group can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group can be optionally substituted with one or more heteroatoms O or S; -R 9 is hydrogen or methyl (preferably -R 9 is hydrogen); M 2+ is a metal cation, A compound or complex or a pharma- ceutically acceptable salt thereof is provided.

[0129] In a particularly preferred embodiment, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -R 1 -CH2OR2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CH2N(R 2 )(R 2’ ), -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) is selected from the group consisting of -R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R 2 are each independently -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)Rβ , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -Rα -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected; Where -R 2 , -R 3 and -R 4 At least one of -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected; -R 2’ , -R 3’ and -R 4’ are each independently selected from hydrogen or C1-C6 alkyl, preferably -R 2’ , -R 3’ and -R 4’ are each independently selected from hydrogen or C1-C3 alkyl; more preferably, -R 2’ , -R 3’ and -R 4’ are each independently selected from hydrogen or methyl; -R α - are C1 to C 42 alkylene groups, where the alkylene group can be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group can be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group, which may be linear or branched or may be or contain a cyclic group, which may be optionally substituted, and which may optionally include one or more (e.g., 1, 2, 3, 4, or 5) heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n-CH3, phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl optionally has one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each of which is -CO2 - and phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X, preferably -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X]; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R3 )(R 3’ ) [preferably -R 7 is -C(O)-N(R 3 )(R 3’ ) and]; -R 8 optionally one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; -R 8’ -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; -R 9 is hydrogen or methyl, preferably -R 9 is hydrogen]; Q is O, S, NH or NMe [preferably Q is O]; X is a halo group; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5 or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) or a pharma- ceutically acceptable salt thereof.

[0130] In a particularly preferred embodiment, the first or second aspect of the invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 1 is -C(O)-N(R 3 )(R 3’ ) and]; -R 2 -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α-X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q]r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected; -R 2 , -R 3 and -R 4 At least one of -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected; -R 3’ and -R 4’are each independently selected from hydrogen or C1-C3 alkyl, preferably -R 3’ and -R 4’ are each independently selected from hydrogen or methyl; -R α - are each independently C1 to C 42 alkylene groups, where the alkylene group can be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group can be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group, which may be linear or branched or may be or contain a cyclic group, which may be optionally substituted, and which may optionally include one or more (e.g., 1, 2, 3, 4, or 5) heteroatoms N, O, S, P or Se in its carbon backbone; -R 5 are each independently selected from C1-C3 alkyl or phenyl, where phenyl is optionally selected from C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 5’ -CO2 - C1-C3 alkyl substituted with -CO2 - phenyl optionally substituted with C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) nmay be further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X, preferably -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X]; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 7 is -C(O)-N(R 3 )(R 3’ ) and]; -R 8 is optionally C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with 1, 2, 3, 4, or 5 substituents independently selected from: -CH3; -R 8’ -CO2 - and optionally substituted with C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; -R 9is hydrogen or methyl, preferably -R 9 is hydrogen]; Q is O, S, NH or NMe [preferably Q is O]; X is a halo group; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5 or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) or a pharma- ceutically acceptable salt thereof.

[0131] In these two preferred embodiments of the preceding paragraph, each -R 5 may be the same or different; preferably, each -R 5 are identical.

[0132] In another preferred embodiment of the first or second aspect of the invention, the compound is a compound of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (IM), (IN), (IO), (IP), (IQ), (IR), (IS), (IT), (IU) or (IV): [ka] TIFF2024542600000023.tif165159TIFF2024542600000024.tif232159TIFF2024542600000025.tif210159TIFF2024542600000026.tif86159, or a metal cation complex thereof, or a pharma- ceutically acceptable salt thereof, wherein -R 1 is -C(O)-OR 3 , -C(O)-SR 3, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) are selected from; -R 2 -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2 or -R α - Selected from X; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2Rβ , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2 or -R α - Selected from X; -R 3’ and -R 4’ are each independently selected from hydrogen or C1-C3 alkyl, preferably -R 3’ and -R 4’ are each independently selected from hydrogen or methyl; -R 6 -OR 2 , -N(R 2 )2, -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X, preferably -R 6 -OR 2 , -SR 2 , -S(O)R 2 , -S(O)2R 2 or -X]; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) are selected from; -R 9 is hydrogen or methyl, preferably -R 9 is hydrogen]; -R α - are C1 to C 12alkylene groups, where the alkylene group can be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group can be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group, which may be linear or branched or may be or contain a cyclic group, which may be optionally substituted, and which may optionally include one or more (e.g., 1, 2, 3, 4, or 5) heteroatoms N, O, S, P or Se in its carbon backbone; -R δ is selected from C1-C3 alkyl; -R ε is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n - selected from CH3; X is a halo group; Y is a counter anion; Z is a counter cation; n is 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5 or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; t is 0, 1, 2, 3, 4 or 5; u is 0, 1, 2, 3, and 4.

[0133] The compounds of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (IM), (IN), (IO), (IP), (IQ), (IR), (IS), (IT), (IU), (IV) and their complexes and salts according to the first and second aspects of the present invention are -[(CH2) p O] r -(CH2) s - includes parts During the ceremony, p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5 or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

[0134] In one embodiment, p is 2, 3 or 4; r is 1; and s is 2, 3 or 4. In a preferred embodiment, p is 3; r is 1; s is 3; -[(CH2) p O] r -(CH2) s - is intended to be -(CH2)3-O-(CH2)3-.

[0135] In another embodiment, p is 2 or 3; r is 2 or 3; and s is 2 or 3. In a preferred embodiment, p is 2; r is 2; s is 2; -[(CH2) p O] r -(CH2) s - is intended to be -(CH2CH2O)2-(CH2)2-.

[0136] In yet another embodiment, r is 0; and s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; -[(CH2) p O] r -(CH2) s -Ha-(CH2) 1-12 -It is supposed to be.

[0137] In another preferred embodiment, the first or second aspect of the invention relates to a compound of formula (I') or a complex of formula (II'): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -U- is -O-, -N(R u )- or -S-; -V- is -CH2-, -O-, -N(R v )- or -S-; -W- is -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] and; -R 11 and -R 12 are each independently selected from -OH or -O-(C1-C4 alkyl); -R α - is C1~C 12 alkylene groups, which may be optionally substituted with one or more (e.g., one, two, three, or four) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., one, two, three, or four) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) nor C-C heteroaryl, where C-C heteroaryl is optionally selected from one or more of C-C alkyl, C-C haloalkyl, -O(C-C alkyl), -O(C-C haloalkyl), halo, -COH, -COZ, -CONH, -O-(CHCHO) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, each of which is -CO2 - wherein phenyl or C5-C6 heteroaryl is optionally substituted with one or more of C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 8 is one or more of C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ -CO2 - and is substituted with one or more of C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally further substituted with -CH3 groups; -R uis hydrogen or C1-C4 alkyl; -R v is hydrogen or C1-C4 alkyl; n is 1, 2, 3, 4, 5 or 6; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation, A compound or complex, or a pharma- ceutically acceptable salt thereof, is provided.

[0138] In another preferred embodiment, the first or second aspect of the invention relates to a compound of formula (I') or a complex of formula (II'): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, -U- is -O-, -N(R u )- or -S-; -V- is -CH2-, -O-, -N(R v )- or -S-; -W- is -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y; -R 11 and -R 12 are each independently selected from -OH or -O-(C1-C4 alkyl); -R α - is C1~C 12 alkylene groups (preferably C1-C9 alkylene groups, preferably C2-C6 alkylene groups), wherein one or more (e.g., 1, 2, 3, or 4, preferably 1 or 2) carbon atoms in the backbone of the alkylene group can be optionally replaced with a heteroatom or group independently selected from O, S, NH or NMe (preferably O, NH or NMe, preferably O); -R 5are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, where phenyl or C5-C6 heteroaryl may be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl) or -O(C1-C4 haloalkyl); -R 8 is -[NC5H5] optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl) or -O(C1-C4 haloalkyl); -R u is hydrogen or C1-C4 alkyl; -R v is hydrogen or C1-C4 alkyl; n is 1, 2, 3, 4, 5 or 6; Y is a counter anion; M 2+ is a metal cation, A compound or complex, or a pharma- ceutically acceptable salt thereof, is provided.

[0139] Preferably, in the compound or complex according to the first or second aspect of the invention, the compound or complex comprises [ka] where Y is a counter anion and q is 0, 1, 2, 3 or 4 (preferably q is 1). or a metal cation complex thereof, or a pharma- ceutically acceptable salt thereof. Preferably, in the compound or complex according to the first or second aspect of the invention, the compound or complex is: [ka] TIFF2024542600000031.tif209159 TIFF2024542600000032.tif200159TIFF2024542600000033.tif201159TIFF2024542600000034.tif204159TIFF2024542600000035.tif96159, or a metal cation complex thereof, or a pharma- ceutically acceptable salt thereof.

[0140] In one embodiment, the compound or complex according to the first or second aspect of the present invention is in the form of a pharma- ceutically acceptable salt. In one embodiment, the compound or complex is in the form of an inorganic salt, such as a lithium, sodium, potassium, magnesium, calcium or ammonium salt. In one embodiment, the compound or complex is in the form of a sodium or potassium salt. In one embodiment, the compound or complex is in the form of a sodium salt. In another embodiment, the compound or complex is in the form of an organic salt, such as an amine salt (e.g., a choline or meglumine salt) or an amino acid salt (e.g., an arginine salt).

[0141] The compound or complex according to the first or second aspect of the invention has at least two chiral centres. The compound or complex according to the first or second aspect of the invention is preferably substantially enantiomerically pure, meaning that the compound or complex contains less than 10%, preferably less than 5%, preferably less than 3%, preferably less than 2%, preferably less than 1%, preferably less than 0.5% (all % by weight) of other stereoisomers as measured by XRPD or SFC.

[0142] Preferably, the compound or complex according to the first or second aspect of the invention has an HPLC purity of greater than 97%, more preferably greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%, more preferably greater than 99.8%, and most preferably greater than 99.9%. As used herein, HPLC purity % is measured by the area normalization method.

[0143] A third aspect of the invention provides a composition comprising a compound or complex according to the first or second aspect of the invention and a pharma- ceutically acceptable carrier or diluent.

[0144] In one embodiment, the composition according to the third aspect of the invention further comprises polyvinylpyrrolidone (PVP). In one embodiment, the composition comprises 0.01-10 w / w% PVP as a percentage of the total weight of the composition, preferably 0.1-5 w / w% PVP as a percentage of the total weight of the composition, preferably 0.5-5 w / w% PVP as a percentage of the total weight of the composition. In one embodiment, the PVP is K30.

[0145] In one embodiment, the composition according to the third aspect of the invention further comprises dimethylsulfoxide (DMSO), in one embodiment the composition comprises 0.01-99 w / w% DMSO as a percentage of the total weight of the composition, preferably 40-99 w / w% DMSO as a percentage of the total weight of the composition, preferably 65-99 w / w% DMSO as a percentage of the total weight of the composition.

[0146] In one embodiment, the composition according to the third aspect of the invention further comprises an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death ligand 1) or CTLA4 (cytotoxic T-lymphocyte associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab or ipilimumab.

[0147] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for use in photodynamic therapy or cytoluminescent therapy.

[0148] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; interstitial pneumonia; The compositions are suitable for the treatment of: intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestines, colon, colorectum, rectum, bladder, ureters, kidneys, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0149] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the treatment of diseases characterised by areas of benign or malignant cellular hyperproliferation or angiogenesis.

[0150] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the treatment of benign or malignant tumours.

[0151] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention are suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0152] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for use in photodynamic diagnosis.

[0153] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; infections by Aidssars viruses (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza Virus, Dengue Virus, Herpes Simplex or Shingles; hepatitis; viral hepatitis; cardiovascular diseases; coronary artery stenosis; carotid artery stenosis; interstitial pneumonia; The device is suitable for detecting: intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestines, colon, colorectum, rectum, bladder, ureters, kidneys, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0154] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the detection of areas affected by benign or malignant cell hyperproliferation or angiogenesis.

[0155] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the detection of benign or malignant tumours.

[0156] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention are suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0157] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for fluorescent or phosphorescent detection of the diseases listed above, preferably for fluorescent or phosphorescent detection and quantification of said diseases.

[0158] Preferably, the compound or complex according to the first or second aspect of the invention, and the pharmaceutical composition according to the third aspect of the invention, are adapted for administration simultaneously with or prior to the administration of radiation or sound, preferably prior to the administration of radiation.

[0159] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention are for use in photodynamic therapy or cytoluminescence therapy, then they are preferably adapted for administration 5 to 100 hours before irradiation, preferably 6 to 72 hours before irradiation, preferably 24 to 48 hours before irradiation.

[0160] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention, are for use in photodynamic diagnosis, then they are preferably suitable for administration 3 to 60 hours before irradiation, preferably 8 to 40 hours before irradiation.

[0161] Preferably, the irradiation used in photodynamic therapy, cytoluminescence therapy or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources are used (e.g., a laser light and an LED light), both radiation sources being suitable for providing irradiation with a wavelength in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. In another embodiment of the present invention, the irradiation can be provided by prostate, anal, vaginal, oral and nasal devices for insertion into body cavities. In another embodiment of the present invention, the irradiation can be provided by mediated photoactivation, for example by inserting a fiber optic laser into the lung, liver, lymph nodes or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0162] The pharmaceutical composition according to the third aspect of the invention may be in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumoral, intraarticular, intraperitoneal, intracranial and epidural), transdermal, airway (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration. The pharmaceutical composition may also be in a form suitable for administration by enema or by injection into a tumor. Preferably, the pharmaceutical composition is in a form suitable for oral, parenteral (such as intravenous, intraperitoneal and intratumoral) or airway administration, preferably in a form suitable for oral or parenteral administration, preferably in a form suitable for oral administration.

[0163] In one preferred embodiment, the pharmaceutical composition is in a form suitable for oral administration. Preferably, the pharmaceutical composition is provided in the form of tablets, capsules, hard or soft gelatin capsules, caplets, lozenges or drops, as a powder or granules, or as an aqueous solution, suspension or dispersion. More preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension or dispersion for oral administration, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is in a form suitable to provide 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the invention.

[0164] In another preferred embodiment, the pharmaceutical composition is in a form suitable for parenteral administration. Preferably, the pharmaceutical composition is in a form suitable for intravenous administration. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution for parenteral administration or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is an aqueous solution or suspension having a pH of 6 to 8.5. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the invention.

[0165] In another preferred embodiment, the pharmaceutical composition is in a form suitable for administration to the respiratory tract. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension or dispersion for administration to the respiratory tract, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the invention.

[0166] A fourth aspect of the invention relates to a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cellular hyperproliferation or vascular There is provided use of a compound or complex according to the first or second aspect of the invention in the manufacture of a medicament for the treatment of a disease characterised by areas of neoplasia; a benign or malignant tumour; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0167] A fourth aspect of the invention provides the use of a compound or complex according to the first or second aspect of the invention in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy. Preferably, the phototherapeutic agent is a compound or complex according to the first or second aspect of the invention for ... The instant compositions are suitable for the treatment of diseases characterized by areas of hyperproliferation of harmful or malignant cells or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0168] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of diseases characterised by areas of benign or malignant cellular hyperproliferation or angiogenesis.

[0169] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of benign or malignant tumours.

[0170] Preferably, the medicament or phototherapy agent according to the fourth aspect of the invention is suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0171] The fourth aspect of the invention also provides the use of a compound or complex according to the first or second aspect of the invention in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.

[0172] Preferably, the photodiagnostic agent of the fourth aspect of the present invention is for use in treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne. ; psoriasis; diseases characterised by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestines, colon, colorectum, rectum, bladder, ureters, kidneys, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0173] Preferably, the photodiagnostic agent according to the fourth aspect of the invention is suitable for the detection of areas affected by benign or malignant cell hyperproliferation or by areas of neovascularization.

[0174] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for the detection of benign or malignant tumours.

[0175] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0176] Preferably, the photodiagnostic agent of the fourth aspect of the present invention is suitable for fluorescent or phosphorescent detection of said disease, preferably for fluorescent or phosphorescent detection and quantification of said disease.

[0177] Preferably, the drug, phototherapeutic agent or photodiagnostic agent is adapted for administration simultaneously with or prior to the administration of radiation or sound, preferably prior to the administration of radiation.

[0178] If the drug or phototherapeutic agent is for use in photodynamic therapy or cytoluminescence therapy, then it is preferably adapted for administration 5 to 100 hours prior to irradiation, preferably 6 to 72 hours prior to irradiation, preferably 24 to 48 hours prior to irradiation.

[0179] If the photodiagnostic agent is used for photodynamic diagnosis, then it is preferably adapted for administration 3 to 60 hours prior to irradiation, preferably 8 to 40 hours prior to irradiation.

[0180] Preferably, the irradiation used in photodynamic therapy, cytoluminescence therapy or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources are used (e.g., a laser light and an LED light), both radiation sources adapted to irradiate wavelengths in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. In another embodiment of the present invention, the irradiation can be provided by prostate, anal, vaginal, oral and nasal devices for insertion into body cavities. In another embodiment of the present invention, the irradiation can be provided by mediated photoactivation, for example, inserting a fiber optic laser into the lung, liver, lymph nodes or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0181] A fifth aspect of the invention relates to a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or non-cancerous conditions. or a disease characterized by areas of malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancers; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. The method comprises administering a therapeutically effective amount of a compound or complex according to the first or second aspect of the invention to a human or animal in need thereof.

[0182] The fifth aspect of the invention also provides a method for photodynamic or cytoluminescent therapy of a human or animal disease, the method comprising administering to a human or animal in need thereof a therapeutically effective amount of a compound or complex according to the first or second aspect of the invention. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes Simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; cutaneous inflammatory ... psoriasis; a disease characterized by areas of benign or malignant hyperproliferation of cells or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

[0183] Preferably, the method of the fifth aspect of the invention is a method of treating areas of benign or malignant cellular hyperproliferation or angiogenesis.

[0184] Preferably, the method of the fifth aspect of the invention is a method of treating a benign or malignant tumor.

[0185] Preferably, the method of the fifth aspect of the invention is a method of treating early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

[0186] The fifth aspect of the invention also provides a method for photodynamic diagnosis of a human or animal disease, the method comprising administering to the human or animal a diagnostically effective amount of a compound or complex according to the first or second aspect of the invention. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes Simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; cutaneous inflammatory ... The disease is preferably a cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchus, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.Preferably, the human or animal disease is characterized by benign or malignant cell hyperproliferation or by areas of angiogenesis.Preferably, the human or animal disease is a benign or malignant tumor. Preferably, the human or animal disease is early stage cancer, cervical dysplasia, soft tissue sarcoma, germ cell tumors, retinoblastoma, age-related macular degeneration, lymphoma, Hodgkin's lymphoma, head and neck cancer, oral cancer, or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. Preferably, the method of photodynamic diagnosis is suitable for fluorescent or phosphorescent detection of said disease, preferably for fluorescent or phosphorescent detection and quantification of said disease.

[0187] In any of the methods of the fifth aspect of the invention, the human or animal is preferably further subjected to irradiation or sound, either simultaneously with or after administration of a compound or complex according to the first or second aspect of the invention. Preferably, the human or animal is subjected to irradiation after administration of a compound or complex according to the first or second aspect of the invention.

[0188] If the method is a method of photodynamic therapy or cytoluminescence therapy, then the human or animal is preferably irradiated 5 to 100 hours, preferably 6 to 72 hours, preferably 24 to 48 hours after administration of the compound or complex according to the first or second aspect of the invention.

[0189] If the method is a method of photodynamic diagnosis, then the human or animal is preferably irradiated 3 to 60 hours, preferably 8 to 40 hours, after administration of the compound or complex according to the first or second aspect of the invention.

[0190] Preferably, the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources are used (e.g., a laser light and an LED light), both radiation sources being suitable for providing irradiation with a wavelength in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. In another embodiment of the present invention, the irradiation can be provided by prostate, anal, vaginal, oral and nasal devices for insertion into body cavities. In another embodiment of the present invention, the irradiation can be provided by mediated photoactivation, for example, inserting a fiber optic laser into the lung, liver, lymph nodes or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0191] In any of the methods of the fifth aspect of the invention, preferably the human or animal is a human.

[0192] In a sixth aspect of the present invention, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: (a) a compound or complex according to the first or second aspect of the invention, and (b) Providing a pharmaceutical combination or kit comprising an immune checkpoint inhibitor.

[0193] In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab or ipilimumab.

[0194] Preferably, the combination or kit of the sixth aspect is for use in the treatment of a disease, disorder or condition, which responds to PD-1, PD-L1 or CTLA4 inhibition. Preferably, the combination or kit of the sixth aspect is for use in the treatment of cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g. non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.

[0195] The sixth aspect also provides the use of a combination or kit of the sixth aspect of the invention in the manufacture of a medicament for the treatment of a disease, disorder or condition responsive to PD-1, PD-L1 or CTLA4 inhibition. The sixth aspect also provides the use of a combination or kit of the sixth aspect of the invention in the manufacture of a medicament for the treatment of cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g. non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.

[0196] The sixth aspect also provides a method of treating a disease, disorder or condition responsive to PD-1, PD-L1 or CTLA4 inhibition, the method comprising administering to a human or animal in need thereof a therapeutically effective amount of the combination or kit of the sixth aspect of the invention. The sixth aspect also provides a method of treating cancer, the method comprising administering to a human or animal in need thereof a therapeutically effective amount of the combination or kit of the sixth aspect of the invention. In one embodiment, the cancer is melanoma, lung cancer (e.g. non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.

[0197] For the combination or kit of the sixth aspect of the invention, the compound or complex according to the first or second aspect of the invention and the immune checkpoint inhibitor may be provided together in one pharmaceutical composition or separately in two pharmaceutical compositions, which, when provided in two pharmaceutical compositions, may be administered at the same time or at different times.

[0198] Preferably, the combination or kit of the sixth aspect is adapted for administration simultaneously with or prior to administration of radiation or sound, preferably prior to administration of radiation. In one embodiment, the combination or kit of the sixth aspect is adapted for administration 5 to 100 hours prior to radiation, preferably 6 to 72 hours prior to radiation, preferably 24 to 48 hours prior to radiation.

[0199] Preferably, the irradiation used in photodynamic therapy or cytoluminescence therapy is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources are used (e.g., a laser light and an LED light), both radiation sources being suitable for providing irradiation with a wavelength in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, preferably 640 nm to 670 nm. In another embodiment of the present invention, the irradiation can be provided by prostate, anal, vaginal, oral and nasal devices for insertion into body cavities. In another embodiment of the present invention, the irradiation can be provided by mediated photoactivation, for example, inserting a fiber optic laser into the lung, liver, lymph nodes or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.

[0200] For the avoidance of doubt, it is to be understood that, so far as is practicable, any embodiment of a given aspect of the invention may occur in combination with any other embodiment of the same aspect of the invention. Further, so far as is practicable, any preferred or optional embodiment of any aspect of the invention is to be taken as a preferred or optional embodiment of any other aspect of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0201] Synthesis Experiment Details Synthesis Example 1

[0202] Methyl (7S,8S)-18-ethyl-7-(3-methoxy-3-oxopropyl)-2,5,8,12,17-pentamethyl-13-(1-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propoxy)ethyl)-7H,8H-porphyrin-3-carboxylate (Compound 1) [ka]

[0203] Synthesis of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-mercaptotetrahydro-2H-pyran-3,4,5-triyl triacetate [ka]

[0204] Step 1: A single-necked 100 mL RBF fitted with a 50 mL addition funnel and nitrogen inlet was charged with 1,2,3,4,6-penta-O-acetyl-β-D-glucose (2.00 g, 5.12 mmol, 1 equiv), a stir bar, and anhydrous DCM (20 mL). The resulting solution was cooled in an ice-water bath under N2 with stirring (420 rpm) for 10 min, after which the addition funnel was charged with 33% w / w HBr / AcOH (8.2 mL, 47 mmol, 9.1 equiv) and added dropwise to the solution over 5 min. After complete addition, the reaction mixture was stirred for 1 h while maintained in the ice-water bath. The mixture was diluted with EtO (100 mL) and washed with HO (3x100 mL) then saturated aqueous NaHCO (2x100 mL) before being dried (MgSO) and concentrated to give crude 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide as a yellow syrup which was used without further purification (2.08 g, 99%).

[0205] 1H NMR (400MHz, CDCl3) δ6.61(d, J=4.1Hz, 1H), 5.56(dd, J=9.7, 9.7Hz, 1H), 5.16(dd, J=10.1, 9.3Hz, 1H), 4.83(dd , J=10.0, 4.1Hz, 1H), 4.37-4.22(m, 2H), 4.17-4.08(m, 1H), 2.10(s, 3H), 2.10(s, 3H), 2.05(s, 3H), 2.03(s, 3H).

[0206] Step 2: The crude glucopyranosyl bromide was dissolved in acetone (20 mL) and added to a 100 mL RBF containing thiourea (0.507 g, 6.66 mmol, 1.3 equiv) and 3A molecular sieves (2.0 g). The resulting mixture was refluxed overnight with stirring (420 rpm) under N2 (external temperature = 80 °C). The product precipitated as a colorless solid. The reaction mixture was diluted with ether (20 mL), filtered through a glass sinter funnel, and washed briefly with ether. The product was separated from the molecular sieves by washing the sinter with MeOH and concentrating the filtrate to give pure 2,3,4,6-tetra-O-acetyl-β-D-glucospiranoyl-1-S-isothiouronium bromide as a colorless solid (1.51 g, 60%). 1 H NMR (400MHz, DMSO) δ9.16(br s, 4H), 5.69(d, J=10.0Hz, 1H), 5.32(dd, J=9.4, 9.4Hz, 1H), 5.16-5.05(m, 2H), 4.25- 4.14(m, 2H), 4.13-4.03(m, 1H), 2.06(s, 3H), 2.02(s, 3H), 2.00(s, 3H), 1.97(s, 3H).

[0207] Step 3: To a 100 mL RBF containing 2,3,4,6-tetra-O-acetyl-β-D-glucospiranoyl-1-S-isothiouronium bromide (1.51 g, 3.10 mmol, 1 equiv.) was added DCM (20 mL) (only partially dissolved), followed by a solution of Na2S2O5 (2.00 g, 10.5 mmol, 3.4 equiv.) in dihydrogen monoxide (20 mL). The heterogeneous mixture was refluxed (external temperature = 70 °C) for 1 h, during which time all material had dissolved. A concentrated aliquot of the organic layer showed clean conversion to the thiol. The organic phase was separated and washed with HO (20 mL) then brine (20 mL) before being dried (MgSO) and concentrated by rotary evaporation to give (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-mercaptotetrahydro-2H-pyran-3,4,5-triyl triacetate as a colorless oil that solidified on standing (1.09 g, 96%).

[0208] 1 H NMR (400MHz, CDCl3) δ5.19(dd, J=9.9, 9.9Hz, 1H), 5.09(dd, J=9.9, 9.9Hz, 1H), 4.97(dd, J=9.9, 9.9Hz, 1H), 4.54(dd, J=9.9, 9.9Hz, 1H), 4.25(dd, J=12.5 , 4.8Hz, 1H), 4.12(dd, J=12.5, 2.3Hz, 1H), 3.72(ddd, J=9.9, 4.8, 2.3Hz, 1H) , 2.31(d, J=9.9Hz, 1H), 2.09(s, 3H), 2.08(s, 3H), 2.02(s, 3H), 2.01(s, 3H).

[0209] Synthesis of methyl (7S,8S)-18-ethyl-7-(3-methoxy-3-oxopropyl)-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-3-carboxylate [ka] A single-necked 250 mL RBF was charged with chlorin e4 (5.0 g, 9.05 mmol, 1 equiv), potassium carbonate (2.75 g, 19.9 mmol, 2.2 equiv) and DMF (100 mL). The resulting solution was stirred under N2 atmosphere (350 rpm) before methyl iodide (1.24 mL, 19.9 mmol, 2.2 equiv) was added in one portion. The reaction was then stirred overnight and monitored by HPLC. The solvent was removed under reduced pressure and the remaining blue solid was purified by repeated column chromatography (5% MeOH / DCM) to give the product as a metallic blue solid (3.61 g, 68.8%).

[0210] 1 H NMR (400MHz, CDCl3) δ9.67(s, 1H), 9.55(s, 1H), 8.73(s, 1H), 8.07(dd, J=17.9, 11.6Hz, 1H), 6.34(dd, J=17 .8, 1.5Hz, 1H), 6.13(dd, J=11.6, 1.5Hz, 1H), 4.50-4.40(m, 2H), 4.30(s, 3H), 3.81(s, 3H), 3.79(q, J=7.6Hz) , 2H), 3.61(s, 3H), 3.58(s, 3H), 3.47(s, 3H), 3.30(s, 3H), 2.62-2.54(m, 1H), 2.49-2.39(m, 1H), 2.26-2.1 8(m, 1H), 1.98-1.88(m, 1H), 1.75(d, J=7.3Hz, 3H), 1.71(t, J=7.6Hz, 3H), -1.49(brs, 1H), -1.68(brs, 1H).

[0211] Synthesis of chlorin e4 3-bromopropyl ether [ka] To a 100 mL RBF containing chlorin e4 dimethyl ester (0.480 g, 0.847 mmol, 1 equiv.) and a stir bar, HBr / AcOH (33% w / w, 6 mL) was added and the deep blue mixture was stirred (420 rpm) at 30 °C (external temperature) for 2 h under N2. 1H NMR analysis showed clean conversion to the bromide. A stream of N2 was run over the sample for a few minutes to remove some of the HBr, then the bulk was concentrated by rotary evaporation. The mixture was then further dried under high vacuum (0.2 mbar) at 40 °C external temperature for 30 min. The residue was reconstituted in DCM (20 mL) before K2CO3 (1.17 g, 8.47 mmol, 10 equiv.) was added followed by 3-bromo-propan-1-ol (1.44 mL, 16.9 mmol, 20 equiv.). The system was flushed with N2 and the dark solution was stirred overnight at 30 °C (external temperature). A concentrated aliquot of the reaction mixture (using a high vacuum pump) showed clean conversion to the ether. The reaction mixture was transferred to a separatory funnel and washed with H2O (20 mL) then brine (20 mL) before being dried (Na2SO4) and concentrated by rotary evaporation to give the crude ether as a dark green oil. The residue was further dried under high vacuum at an external temperature of 40° C. for 30 min and an attempt was made to distill off excess 3-bromo-propan-1-ol to obtain 1.93 g of final crude mass. The residue was purified by column chromatography (25% EtOAc / Hexane, loaded as a solution on eluent, R f =0.4, visualized by UV) to give chlorin e4 3-bromopropyl ether as a dark green film (302 mg, 51%).

[0212] Synthesis of methyl (7S,8S)-18-ethyl-7-(3-methoxy-3-oxopropyl)-2,5,8,12,17-pentamethyl-13-(1-(3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)propoxy)ethyl)-7H,8H-porphyrin-3-carboxylate (Compound 1) [ka] Step 1: Chlorin e4 To a 50 mL RBF containing 3-bromopropyl ether (0.214 g, 0.297 mmol, 1 equiv.) was added CHCl3 (3 mL), (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-mercaptotetrahydro-2H-pyran-3,4,5-triyl triacetate (92% w / w, 0.389 g, 0.981 mmol, 3.3 equiv.), followed by triethylamine (0.24 mL, 1.8 mmol, 5.9 equiv.). The dark green mixture was stirred (420 rpm) at 30 °C (external temperature) under N2 and the progress of the reaction was monitored by TLC (25% EtOAc / Hexanes). After stirring overnight, the reaction mixture was washed with HO (10 mL). The organic phase was collected, dried (Na2SO4) and concentrated by rotary evaporation to give the crude coupled product as a dark green film (677 mg). The residue was purified by column chromatography (0-10% MeOH / DCM) to give chlorin e4 dimethyl ester propyloxythio-D-glucose peracetate (261 mg).

[0213] Step 2: To a solution of chlorin e4 dimethyl ester propyloxythio-D-glucose peracetate (0.261 g, 0.260 mmol, 1 equiv) in a mixture of DCM (4 mL) and MeOH (4 mL) was added dropwise a 4.6 M solution of NaOMe in MeOH (0.57 mL, 2.60 mmol, 10 equiv). The dark green solution was stirred at ambient temperature for 20 min and reaction completion was confirmed by TLC (3% MeOH / DCM). The reaction was quenched with AcOH (10 drops) and concentrated by rotary evaporation. The residue was partitioned between DCM (10 mL) and H2O (10 mL) and the organic phase was collected and washed with brine (10 mL). The organic phase was dried (Na2SO4) and concentrated by rotary evaporation to give the crude deacetylated product as a dark green film (267 mg). The residue was purified by column chromatography (5-15% MeOH / DCM) to give compound 1 as a dark green foam (92 mg, 37%-over two steps).

[0214] Synthesis Example: Synthesis of 2-methyl 3-((7S,8S)-18-ethyl-3-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)(methyl)carbamoyl)-2,5,8,12,17-pentamethyl-13-(2,5,8,11-tetraoxatridecan-12-yl)-7H,8H-porphyrin-7-yl)propanoate (Compound 2) [ka] Step 1: [ka] A single-necked 250 mL RBF was fitted with a short air condenser and charged with chlorin e4 (1.00 g, 1.81 mmol), potassium carbonate (0.26 g, 1.90 mmol, 1.05 equiv), and DMF (130 mL). The resulting solution was stirred (420 rpm) under a N2 atmosphere before methyl iodide (0.10 mL, 1.63 mmol, 0.9 equiv) was added in one portion. The reaction was stirred at 30 °C for 16 h, cooled to room temperature, and concentrated under reduced pressure. HPLC analysis of the remaining blue solid indicated the presence of starting material and the dimethyl ester. The crude residue was heated to reflux in acetone (40 mL), cooled, and then refrigerated overnight. The precipitate was collected by vacuum filtration onto a paper filter to give a metallic blue solid (578 mg, 56%). This material was adsorbed onto silica gel and purified by column chromatography (1% to 30% MeOH in CH2Cl2) to give the desired product as a metallic blue solid.

[0215] 1H NMR (400MHz, d6-DMSO)9.74(s, 1H), 9.65(s, 1H), 9.05(s, 1H), 8.29(dd, J=17.8, 11.6Hz, 1H), 6.4 5(dd, J=17.8, 1.6Hz, 1H), 6.18(dd, J=11.6, 1.4Hz, 1H), 4.59(q, J=7.1Hz, 1H), 4.49(d, J=10.1Hz , 1H), 4.25(s, 3H), 3.79(q, J=7.5Hz, 2H), 3.74(s, 3H), 3.54(s, 3H), 3.50(s, 3H), 2.70-2.55(m, 1 H), 2.39-2.26(m, 2H), 1.70(d, J=7.2Hz, 3H), 1.67(t, J=7.6Hz, 4H), -1.67(s, 1H), -1.88(s, 1H).

[0216] Step 2: [ka] A 50 mL RBF fitted with a nitrogen inlet was charged with a small stir bar, 2-(2-(2-methoxyethoxy)ethoxy)-N-methylethan-1-amine (75 mg, 0.424 mmol, 1.2 equiv), chlorin e4 monomethyl ester (87% w / w, 230 mg, 0.353 mmol, 1 equiv), triethylamine (147 μL, 1.06 mmol, 3 equiv), and DCM (5 mL). To the resulting dark green solution was added PyBOP (202 mg, 0.388 mmol, 1.1 equiv) and the mixture was stirred under N2 for 1 h. At this point, TLC analysis (5% MeOH / DCM, R f (starting material) = 0.4, R f(product)=0.45, visualized by UV) indicated clean conversion. The reaction mixture was concentrated by rotary evaporation and the residue was purified by Biotage autocolumn chromatography to give the desired product. The product was taken up in EtOAc (20 mL) and washed with H2O (3 x 20 mL). The organic phase was dried (Na2SO4) and concentrated by rotary evaporation to give methyl 3-((7S,8S)-18-ethyl-3-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)(methyl)carbamoyl)-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)propanoate as a blue / brown film (233 mg, 91%).

[0217] 1 H NMR (400MHz, CDCl3) δ9.66(s, 1H), 9.54(s, 1H), 8.74(s, 1H), 8.06(dd, J=17.8, 11.5Hz, 1H), 6.3 5(dd, J=17.8, 1.5Hz, 1H), 6.13(dd, J=11.5, 1.6Hz, 1H), 4.58(dd, J=8.5, 2.5Hz, 1H), 4.49(app. q, J=7.3Hz, 1H), 4.30(s, 3H), 3.85(s, 3H), 3.80(app. q, J=7.6Hz, 2H), 3.59(s, 3H), 3.55-3.49(m, 4H), 3.48(s, 3H), 3.47-3.38(m, 3H), 3.31(s, 3H), 3.29-3.22(m, 4H), 3.11-2.90(m).

[0218] Step 3: [ka] To a 50 mL RBF containing methyl 3-((7S,8S)-18-ethyl-3-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)(methyl)carbamoyl)-2,5,8,12,17-pentamethyl-13-vinyl-7H,8H-porphyrin-7-yl)propanoate (0.50 g, 0.689 mmol, 1 equiv.) and a stir bar, HBr / AcOH (33% w / w, 5 mL) was added and the dark blue mixture was stirred (350 rpm) under N2 at 30 °C for 2 h. A stream of N2 was passed over the sample for a few minutes to remove some of the HBr before concentrating the bulk by rotary evaporation. The mixture was further dried under high vacuum (1.5 mbar) with heating (40 °C) for 30 min. The residue was reconstituted in DCM (20 mL) followed by the addition of K2CO3 (0.95 g, 6.89 mmol, 10 equiv.) and triethylene glycol monomethyl ether (1.13 g, 6.89 mmol, 10 equiv.). The dark solution was stirred at 30 °C (external temperature) overnight. HPLC analysis showed three major peaks (including starting material). The reaction mixture was transferred to a separatory funnel, diluted with DCM (20 mL), washed with H2O (50 mL) and then with brine (50 mL), before being dried (Na2SO4) and concentrated to give the crude coupled product as a dark green oil (0.80 g). The crude material was purified by silica column chromatography (1-2% MeOH / DCM). The fractions containing the product (R in 5% MeOH / DCM) were f The crude product was loaded as a solution in DCM pre-filtered through a 0.45 μm syringe filter and eluted with 0-5% MeOH to give the product, compound 2, as a dark green viscous oil (260 mg, 42.6%) (HPLC purity: 93.1%).

[0219] Synthesis Example 3 - Synthesis of chlorin e4 dimethyl ester 13-(6-(triphenylphosphonium bromide)hexyl)carbamate (compound 3) [ka] Step 1: To a 50 mL RBF was added (6-((tert-butoxycarbonyl)amino)hexyl)triphenylphosphonium bromide (1.00 g, 1.843 mmol, 9.7 equiv), DCM (10 mL) and TFA (2 mL). The resulting solution was stirred at ambient temperature (420 rpm) for 1 h and then concentrated on a rotary evaporator. The residue was resuspended and concentrated twice from chloroform (2×40 mL) to give 6-aminohexyltriphenylphosphonium bromide TFA as a viscous oil (1.814 g), which was dissolved in DCM (2 mL) for the next coupling reaction.

[0220] Step 2: To a 100 mL RBF was added chlorin e4 dimethyl ester (1.98 g, 3.41 mmol, 1 equiv), THF (75 mL), osmium tetroxide (8.7 mg, 0.0341 mmol, 0.01 equiv), deionized water (6 mL), AcOH (6 mL) and sodium periodate (1.90 g, 8.87 mmol, 2.6 equiv). The resulting mixture was stirred in the dark under nitrogen at ambient temperature for 18 h (420 rpm). The reaction mixture was concentrated using a rotary evaporator to remove THF, then redissolved in DCM (100 mL), transferred to a separatory funnel and washed with brine (50 mL), saturated NaHCO3 (50 mL) and water (80 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give a dark blue solid (2.26 g). The crude product was purified by silica gel column chromatography using an eluent gradient of 1.5-4% MeOH in DCM. The first major band (R f =0.7) was concentrated by rotary evaporation to give chlorin e4 13-formyldimethyl ester as a dark blue solid (1.18 g, 59%).

[0221] 1H NMR (400MHz, CDCl3) δ11.54(s, 1H), 10.23(s, 1H), 9.64(s, 1H), 8.95(s, 1H), 4.57-4.43(m, 2H), 4 .33(s, 3H), 3.86(s, 3H), 3.84-3.72(m, 6H), 3.64(s, 3H), 3.60(s, 3H), 3.32(s, 3H), 2.64(dt, J=1 5.9, 8.0Hz, 1H), 2.47(dtd, J=14.1, 8.0, 2.9Hz, 1H), 2.29(ddd, J=15.8, 8.2, 4.9Hz, 1H), 1.97-1. 83(m, 1H), 1.78(d, J=7.2Hz, 3H), 1.72(t, J=7.6Hz, 3H), 1.57(s, 1H), -1.50(s, 1H), -2.01(s, 1H).

[0222] Step 3: To a 100 mL RBF was added chlorin e4 13-formyl dimethyl ester (851 mg, 1.46 mmol, 1 equiv), MeOH (20 mL), DCM (10 mL) and sodium borohydride (110 mg, 2.92 mmol, 2 equiv). The resulting mixture was stirred (400 rpm) at ambient temperature with nitrogen for 1 h. The reaction mixture was diluted with water (50 mL) and stirred for 10 min. The mixture was then diluted with DCM (20 mL) and brine (20 mL). The DCM layer was collected and the aqueous layer was further extracted with DCM (20 mL). The combined DCM layers were washed with brine (30 mL), dried (Na2SO4) and concentrated by rotary evaporation to give a dark blue solid (902 mg) which was purified by chromatography. The crude product was dissolved in DCM and eluted with 2-5% MeOH / DCM. The product (large dark green spot, R f Fractions containing 13-hydroxymethyldimethyl ester (=0.6 in 5% MeOH / DCM) were combined to give chlorin e4 13-hydroxymethyldimethyl ester as a dark blue solid (601 mg, 70%). 1H NMR (400MHz, CDCl3) δ9.65(s, 1H), 9.45(s, 1H), 8.73(s, 1H), 5.76(s, 2H), 4.54-4.40(m, 2H), 4.30(s, 3H), 3.82(s, 3H), 3.74(q, J=7.4Hz, 2H), 3.60(s, 3H), 3.57(s, 3H), 3.39(s, 3H), 3.26 (s, 3H), 2.58(dt, J=15.8, 8.0Hz, 1H), 2.49-2.38(m, 1H), 2.27-2.15(m, 1H), 1.93(dtd, J=14. 1, 9.1, 4.9Hz, 1H), 1.75(d, J=7.2Hz, 3H), 1.70(t, J=7.6Hz, 3H), -1.64(s, 1H), -1.83(s, 1H). Step 4: To a 50 mL RBF was added chlorin e4 13-hydroxymethyldimethyl ester (100 mg, 0.171 mmol, 1 equiv), carbonyldiimidazole (55 mg, 0.342 mmol, 2 equiv), DCM (5 mL) and DMAP (10 mg). The resulting mixture was stirred under nitrogen for 3 h with TLC monitoring. TEA (1.17 g, 11.6 mmol) was added followed by 6-aminohexyltriphenylphosphonium bromide (1.814 g, containing approximately 1.01 g TFA in 2 mL DCM) and stirring was continued for 4 days. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel and washed with 1 M HCl (2x25 mL) and pH=7 phosphate buffer (25 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography (4×18 cm) using 5-8% MeOH / DCM loaded as a solution to eluent. f Fractions containing 3 (methylene blue = 0.30 in 10% MeOH / DCM) were combined and concentrated by rotary evaporation to give compound 3 (106 mg, 59%). 1H NMR (400MHz, CDCl3) δ9.63(s, 1H), 9.58(s, 1H), 8.73(s, 1H), 7.67-7.51(m, 9H), 7.51-7.39(m, 5H), 6.37(s, 2H), 5.69(t, J=5. 9Hz, 1H), 4.49-4.38(m, 2H), 4.29(s, 3H), 3.80(s, 3H), 3.75(q, J=7.9Hz, 2H), 3.60(s, 3H), 3.56(s, 6H), 3.48(s, 3H), 3.28(s, 3) H), 3.23(q, J=6.4Hz, 2H), 2.58(dt, J=15.9, 8.0Hz, 1H), 2.42(ddd, J=14.1, 8.7, 6.0Hz, 1H), 2.28-2.15(m, 1H), 1.89(dtd, J=14 .0, 9.0, 4.9Hz, 1H), 1.77-1.62(m, 12H), 1.62-1.52(m, 1H), 1.51-1.39(m, 1H), 1.39-1.29(m, 1H), -1.62(s, 1H), -1.84(s, 1H).

[0223] Synthesis Example 4 - Synthesis of chlorin e4 dimethyl ester 13-(N-(3-(3-triphenylphosphoniumpropoxy)propyl)chloride)carbamate (compound 4) [ka] Step 1: A 500 mL 3-necked RBF equipped with a 3 cm stir bar was charged with bis(3-chloropropyl)ether (20.00 g, 70.15 mmol, 1.66 equiv), triphenylphosphine (18.40 g, 70.15 mmol, 1 equiv), sodium iodide (7.01 g, 46.77 mmol, 0.66 equiv) and acetonitrile (340 mL). The RBF was placed over a water bath, fitted with an air condenser and stirring (500 rpm) was started under N2 at an external temperature of 90 °C. The mixture was allowed to stir for 72 h. After this time, the reaction flask was cooled to room temperature and the suspension was filtered through a 2 cm plug of Celite® and washed with acetonitrile (250 mL). The pale yellow solution was then evaporated to dryness to give a dark yellow oil (44.40 g) which was subjected to column chromatography (silica gel, 9x12 cm) using 6% MeOH in DCM as the eluent. f The fractions with Rf=0.35 were combined and concentrated by rotary evaporation. The resulting residue was further purified by column chromatography (silica gel, 9×7 cm). DCM was used as the eluent until no triphenylphosphine was observed by TLC, then the eluent was changed to 10% MeOH in DCM and the product was removed from the column. The fractions with Rf=0.35 as visualized by UV in 6% MeOH / DCM were combined and concentrated by rotary evaporation to give (3-(3-chloropropoxy)propyl)triphenylphosphonium chloride as a pale red solid (18.74 g, 62%).

[0224] 1 H NMR (400MHz, CDCl3) δ7.87-7.76(m, 9H), 7.75-7.63(m, 6H), 3.93-3.80(m, 2H), 3.75(td, J=5.7, 1.3Hz, 2H), 3.58(q, J=6.3Hz, 4H), 2.05-1.88(m, 4H).

[0225] Step 2: To a 50 mL RBF was added (3-(3-chloropropoxy)propyl)triphenylphosphonium chloride (4.0 g, 9.23 mmol, 1 eq), NaN3 (11.08 g, 1.2 eq), NaBr (38 mg, 0.04 eq), tetrapropylammonium bromide (49 mg, 0.02 eq) and water (10 mL). After connecting a water condenser, the flask was heated at 110° C. with stirring for 44 h. Then the mixture was cooled and EtOAc (50 mL) was added. The mixture was transferred to a separatory funnel and washed with water (3×30 mL) and brine (30 mL). The combined aqueous layers were extracted with DCM (3×20 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give (3-(3-azidopropoxy)propyl)triphenylphosphonium chloride as a pale yellow solid (3.20 g, 79%).

[0226] 1 H NMR (400MHz, CDCl3) δ7.86-7.77(m, 9H), 7.73-7.66(m, 6H), 3.90-3.80(m, 2 H), 3.75(t, 2H), 3.53(t, 2H), 3.33(t, 2H), 1.99-1.89(m, 2H), 1.82(p, 2H).

[0227] Step 3: A three-necked 100 mL RBF was charged with (3-(3-azidopropoxy)propyl)triphenylphosphonium chloride (1.00 g, 2.273 mmol, 1 equiv), 10% Pd / C (20 mg), methanol (10 mL) and a stir bar. A hydrogen balloon was connected to the center joint of the flask via a short air condenser and the side arm was connected to a 3-way tap. The setup was evacuated and then back-filled with nitrogen (3 times), evacuated and back-filled with hydrogen (2 times). The resulting solution was stirred (550 rpm) under hydrogen atmosphere at 35 °C for 2 h. The solution was then filtered through Celite® (0.5x3 cm), washed with chloroform (2x10 mL) and the solvent removed under reduced pressure to give (3-(3-aminopropoxy)propyl)triphenylphosphonium chloride as a viscous oil which solidified on standing (1.05 g, quantitative).

[0228] 1 H NMR (400MHz, CDCl3) δ7.86-7.76(m, 9H), 7.73-7.66(m, 6H), 3.88-3.79(m, 2H), 3.7 3(t, 2H), 3.51(t, 2H), 2.75(t, 2H), 1.99-1.87(m, 2H), 1.68(p, 2H), 1.41(brs, 2H).

[0229] Step 4: To a 50 mL RBF was added chlorin e4 13-hydroxymethyldimethyl ester (100 mg, 0.171 mmol, 1 equiv), carbonyldiimidazole (55 mg, 0.342 mmol, 2 equiv), DCM (5 mL) and DMAP (10 mg). The resulting mixture was stirred under nitrogen for 3 h with TLC monitoring. (3-(3-aminopropoxy)propyl)triphenylphosphonium chloride (354 mg, 0.855 mmol, 5 equiv, in 2 mL DCM) was added and stirring was continued for 20 h. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel and washed with 1M HCl (2x25 mL) and pH=7 phosphate buffer (25 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give a dark green residue. The residue was purified by column chromatography with 5% MeOH / DCM loaded as a solution to the eluent. Large dark green spot (R in 5% MeOH / DCM f =0.20) were combined to give compound 4 (113 mg, 64%).

[0230] 1H NMR (400MHz, CDCl3) δ9.66(s, 1H), 9.55(s, 1H), 8.74(s, 1H), 7.66-7.51(m, 6H), 7.51-7.36(m, 10H), 6.35(s, 2H), 5.46(t, J=5.9Hz, 1H), 4.50-4.40(m, 2H), 4.30(s, 3H), 3.81(s, 3H), 3.77(q, J=7.7Hz, 2H), 3.71-3.62(m, 4H), 3.60(s, 3H), 3.58(s, 3H), 3.51(t, J=5.8Hz, 1H), 3.45(s, 3H), 3.38(q, J=6.3Hz, 2H), 3.27(s, 3H), 2.59(dt, J=15.8, 8.0Hz, 1H), 2.42(ddt, J=10. 5, 7.8, 4.2Hz, 1H), 2.28-2.16(m, 1H), 1.90(dtd, J=14.1, 9.0, 4.9Hz, 1H), 1.81-1.64(m, 11H), -1.63(s, 1H), -1.86(s, 1H).

[0231] Synthesis Example 5 - Synthesis of chlorin e4 dimethyl ester 13-(N-(3-triphenylphosphoniumpropyl) bromide) carbamate (compound 5) [ka] To a 25 mL RBF was added chlorin e4 13-hydroxymethyldimethyl ester (120 mg, 0.205 mmol, 1 equiv), carbonyldiimidazole (66 mg, 0.410 mmol, 2 equiv), DCM (3 mL) and DMAP (5 mg). The resulting mixture was stirred under nitrogen for 3 h with TLC monitoring. A solution of (3-aminopropyl)triphenylphosphonium bromide (412 mg, 1.03 mmol, 5 equiv) in DCM (5 mL) was added and stirring was continued for 16 h. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel and washed with 1 M hydrochloric acid (2x25 mL) and pH=7 phosphate buffer (25 mL), then dried (Na2SO4) and concentrated by rotary evaporation to give a dark blue-green residue. The residue was purified by column chromatography using 5-10% MeOH / DCM loaded as a solution in 5% MeOH / DCM. Large dark green spot (R in 5% MeOH / DCMf =0.20) were combined to give compound 5 as a dark blue solid (104 mg, 50%).

[0232] 1 H NMR (400MHz, CDCl3) δ9.75(s, 1H), 9.67(s, 1H), 8.77(s, 1H), 7.80(s, 1H), 7.50-7.38(m, 6H), 7.23-7.10(m, 10H), 6.95(s , 1H), 6.69(s, 1H), 6.39(s, 2H), 4.46(dq, J=14.5, 7.9, 7.2Hz, 2H), 4.31(s, 3H), 3.83(s, 3H), 3.81-3.65(m, 2H), 3.62(s, 3) H), 3.59(s, 3H), 3.53(s, 4H), 3.32(s, 3H), 2.61(dt, J=15.8, 8.0Hz, 1H), 2.44(q, J=8.6, 8.1Hz, 1H), 2.25(ddd, J=15.6, 8 .5, 4.9Hz, 1H), 1.97-1.85(m, 1H), 1.80(s, 3H), 1.75(d, J=7.2Hz, 2H), 1.68(t, J=7.6Hz, 4H), -1.63(s, 1H), -1.76(s, 1H).

[0233] Synthesis Example 6 - Synthesis of chlorin e4 dimethyl ester 13-(N-(2-triphenylphosphonium ethyl) bromide) carbamate (compound 6) [ka] To a 25 mL RBF was added chlorin e4 13-hydroxymethyldimethyl ester (120 mg, 0.205 mmol, 1 equiv), carbonyldiimidazole (66 mg, 0.410 mmol, 2 equiv), DCM (3 mL) and DMAP (5 mg). The resulting mixture was stirred under nitrogen for 3 h and the reaction progress was monitored by TLC. A solution of 2-aminoethyltriphenylphosphonium bromide (398 mg, 1.03 mmol, 5 equiv) in DCM (5 mL) was added and stirring was continued for 18 h. The reaction mixture was diluted with DCM (20 mL), transferred to a separatory funnel and washed with 1 M HCl (2x25 mL) and pH=7 phosphate buffer (25 mL) before being dried (Na2SO4) and concentrated by rotary evaporation to give a dark blue-green residue. The residue was purified by column chromatography using 5%-7.5%-10% MeOH / DCM as eluent, loaded as a solution in 5% MeOH / DCM. f =0.37) was concentrated by rotary evaporation to give compound 6 as a dark blue solid (71 mg, 35%).

[0234] 1 H NMR (400MHz, CDCl3) δ9.66(s, 1H), 9.61(s, 1H), 8.76(s, 1H), 7.73-7.57(m, 7H), 7.44-7.35(m, 8 H), 6.25(s, 2H), 4.53-4.40(m, 2H), 4.29(s, 3H), 3.89-3.70(m, 7H), 3.60(s, 3H), 3.58(s, 3H), 3. 47(s, 3H), 3.32(s, 3H), 2.59(dt, J=15.8, 7.9Hz, 1H), 2.51-2.37(m, 1H), 2.23(ddd, J=15.4, 8.3 , 4.9Hz, 1H), 1.92(dtd, J=14.1, 9.0, 4.9Hz, 1H), 1.83-1.64(m, 8H), -1.64(s, 1H), -1.82(s, 1H).

[0235] Synthesis Example 7 - Synthesis of Chlorin e4 13-(N-methyl-5-triphenylphosphonium bromide pentanamide) dimethyl ester (compound 7) [ka] Step 1: To a 250 mL RBF was added chlorin e4 13-formyldimethyl ester (1.0 g, 1 equiv), DCM (20 mL), methanol (80 mL), TEA (289 mg, 3 equiv) and methylamine hydrochloride (434 mg, 3 equiv). The resulting mixture was stirred under nitrogen in the dark for 2 h, an additional portion of methylamine hydrochloride (434 mg, 3 equiv), TEA (289 mg, 3 equiv) and 4 Å sieves (100 mg) was added and stirring was continued for 4 h. NaBH4 (72 mg, 1.906 mmol, 10 equiv) was added and stirring was continued for 12 h. The reaction was acidified with 2 M HCl (10 mL) and stirred for 10 min. Phosphate buffer pH=7 (30 mL) was added and the mixture was extracted with DCM (3×50 mL). The combined organics were dried (Na2SO4) and concentrated by rotary evaporation to give a dark green residue, which was subjected to silica gel column chromatography. The crude product was dissolved in DCM and loaded onto a column previously equilibrated with DCM. The column was eluted with a gradient of 3-7% MeOH / DCM. Fractions containing the product (large dark green spot, R at 10% MeOH / DCM) were f =0.3) were combined to give chlorin e4 13-N-methylaminodimethyl ester as a dark green solid (600 mg, 58%).

[0236] 1 H NMR (400MHz, CDCl3) δ9.51(s, 1H), 9.42(s, 1H), 8.68(s, 1H), 4.82(brm, 2H), 4.41(m, 2H), 4.29(s, 3H), 3.82(s, 3H), 3.71(q, 2H), 3.62-3.58(m, 3H), 3.52(s, 3H), 3.48(s, 3 H), 3.32(s, 3H), 3.25(s, 3H), 2.62(s, 3H), 2.59-2.50(m, 2H), 2.40-2.30(m, 2H), 2.20 -2.10(m, 1H), 1.88-1.74(m, 1H), 1.70-1.60(m, 6H), -1.65(brs, 1H), -1.90(brs, 1H).

[0237] Step 2: To a 50 mL RBF was added chlorin e4 13-N-methylaminodimethyl ester (200 mg, 1 equiv.), (4-carboxybutyl)triphenylphosphonium bromide (296 mg, 2 equiv.), DCM (10 mL) and DMTMM (184 mg, 2 equiv.). The resulting mixture was stirred (250 rpm) under nitrogen at ambient temperature in the dark. After 10 min TEA (5 drops) was added and stirring was continued for an additional 2 h. The reaction mixture was transferred to a separatory funnel, diluted with DCM (30 mL) and washed with water (10 mL). The aqueous layer was re-extracted with DCM (2x5 mL). The organic phase was dried (Na2SO4) and concentrated by rotary evaporation to give a blue-black film, which was subjected to column chromatography. The crude product was dissolved in DCM and eluted using a gradient of 4-7% MeOH / DCM. Fractions containing the product (large dark green spot, R at 7% MeOH / DCM) were analyzed by column chromatography. f =0.3) were combined and concentrated by rotary evaporation to give compound 7 (320 mg, 93%).

[0238] 1 H NMR (400MHz, CDCl3) δ9.71(s, 1H), 9.62(s, 1H), 8.70(s, 1H), 7.75-7.67(m, 6H), 7.55-7.45(m, 9H), 5.8 5(brm, 2H), 4.50-4.40(m, 2H), 4.29(s, 3H), 4.02-3.82(m, 2H), 3.80-3.70(m, 5H), 3.62(s, 3H), 3.55(s , 3H), 3.42(s, 3H), 3.20(s, 3H), 3.12(s, 3H), 2.82(t, 2H), 2.61-2.52(m, 1H), 2.48-2.33(m, 1H), 2.25- 2.10(m, 5H), 2.00-1.80(m, 3H), 1.75-1.70(m, 3H), 1.69-1.61(m, 3H), -1.60(brs, 1H), -1.80(brs, 1H).

[0239] Synthesis Example 8 - Synthesis of chlorin e4 dimethyl ester 13-(N-methyl-(3-triphenylphosphoniumpropoxy) chloride) carbamate (compound 8) [ka] To a 25 mL RBF was added chlorin e4 13-N-methylaminodimethyl ester (100 mg, 0.167 mmol, 1 equiv), carbonyldiimidazole (54 mg, 0.334 mmol, 1.5 equiv) and DCM (4 mL). The resulting mixture was stirred (300 rpm) under nitrogen for 1 h. (3-Hydroxypropyl)triphenylphosphonium chloride (119 mg, 0.334 mmol, 1.5 equiv) in DCM (2 mL) was added and stirring was continued at 23° C. overnight in the dark. The reaction mixture was then diluted with DCM (15 mL), transferred to a separatory funnel, washed with water (15 mL), extracted with DCM (2×5 mL), dried (Na2SO4) and concentrated by rotary evaporation to give a dark green residue. The residue was subjected to column chromatography. The residue was dissolved in DCM and loaded onto a column pre-equilibrated with DCM. The column was eluted with a gradient of 3–8% MeOH / DCM. Fractions containing the product (large dark green spot, R 1 at 7% MeOH / DCM) were f =0.25) were combined to give compound 8 as a dark green solid (72 mg, 44%).

[0240] 1 H NMR (400MHz, CDCl3) δ9.73(s, 1H), 9.55(s, 1H), 8.72(m, 1H), 7.75-7.60(m, 6H) , 7.42-7.30(m, 9H), 5.82-6.68(m, 2H), 4.62(m, 1H), 4.41(m, 2H), 3.85-3.70(m, 5H), 3.60(m, 6H), 3.45-3.35(m, 3H), 3.20(s, 3H), 2.62-2.46(m, 2H), 2.25-2.00 (m, 4H), 1.92-1.84(m, 4H), 1.80-1.65(m, 8H), -1.55(brs, 1H), -1.75(brs, 1H). EXAMPLES

[0241] Biological Experiment Details Example 1 - Solubility Measurement of Chlorin e4 Analogues The absorbance maximum was used as a surrogate measure of solubility. Related chlorin e4 analogues were diluted to 50 μM in PBS (phosphate buffered saline) solutions containing decreasing amounts of DMSO from 100% to 0%.

[0242] Where necessary, polyvinylpyrrolidone (K30) was added to a final concentration of 1 w / v%. Absorbance was measured using a Cytation3 multimode plate reader (Biotek) in spectral scanning mode, and spectra were captured between 500 and 800 nm in 2 nm increments. An equivalent volume of blank solution was also measured and subtracted accordingly. Each spectrum was normalized to have a minimum signal of 0, and a maximum signal in 100% pure DMSO solution (the most soluble state).

[0243] Example 2 - Cytotoxicity, Phototoxicity and Therapeutic Index Preparation of photosensitizer stock solution Photosensitizers (e.g., chlorin e4 analogs, chlorin e4 disodium (provided by Advanced Molecular Technologies (Scoresby)) or talaporfin sodium (purchased from Focus Bioscience catalog number HY-16477-5MG)) were resuspended in 100% dimethyl sulfoxide (DMSO) at a concentration of 5.5 mM. Samples were stored at 4°C protected from light.

[0244] Preparation of photosensitizers for in vitro testing For in vitro experiments, photosensitizers (5.5 mM stock solution in 100% DMSO) were diluted 1:100 in concentrated excipient solution (55 μM final photosensitizer in 10% w / v Kollidon-12, 42.4% w / v polysorbate 80, 0.6% w / v anhydrous citric acid, 40% w / v ethanol, 1.0% DMSO). Serial dilutions were prepared at a constant dilution rate of 1:55 in cell culture medium (Dulbecco's modified Eagle's medium / nutrient mixture F-12 (DMEM / F-12)) supplemented with 10% v / v fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin, and the same excipient solution.

[0245] cell culture The human ovarian cancer cell line SKOV3 (ATCC#HTB-77) was maintained in Dulbecco's modified Eagle's medium / nutrient mixture F-12 (DMEM / F-12) supplemented with 10% v / v fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. Monolayer cultures were grown in a humidified incubator at 37°C with 5% CO2. When the cells reached approximately 80% confluence, the spent medium was replaced with medium containing the photosensitizer at the required concentration, and the cells were incubated for the required time to allow for uptake of the photosensitizer.

[0246] statistical analysis All data were analyzed using GraphPad PRISM v8.3.1(549) (GraphPad Software (CA)). Spectral absorbance and viability measurements were normalized to a range of 0-100%, with the minimum being 0 and the maximum being determined from the data set. Dose-response was determined using sigmoidal 4-point nonlinear regression with variable slope, and IC10 or IC90 was calculated for each compound. All data are presented as mean ± SD (where applicable).

[0247] cytotoxicity SKOV3 cells were seeded in 96-well black wall plates (Greiner #655090) at a cell density of 5000 cells per well in 100 μl of medium. Upon reaching approximately 60% confluence, the medium was aspirated and replaced with fresh medium containing 0-100 μM of the relevant chlorin e4 analogue in DMSO. Cells were incubated for an additional 24 h to allow uptake of the chlorin e4 analogue.

[0248] To test the intrinsic cytotoxicity (i.e. "dark toxicity") of chlorin e4 analogues, the medium was replaced with fresh medium containing 10% (v / v) AlamarBlue cell viability reagent (ThermoFisher) after 24 h and cells were incubated at 37°C for 6 h. Untreated cells were used as control. Fluorescence (Ex555nm / Em596nm) was measured using a Cytation 3 Cell Imaging Multi-Mode reader (Biotek) and cytotoxicity was assessed according to the percentage of viable cells remaining. All measurements were performed in quadruplicate.

[0249] phototoxicity SKOV3 cells were seeded in 96-well black wall plates (Greiner #655090) at a cell density of 5000 cells per well in 100 μl of medium. Upon reaching approximately 60% confluence, the medium was aspirated and replaced with fresh medium containing 0-100 μM of the relevant chlorin e4 analogue in DMSO. Cells were incubated for an additional 24 h to allow uptake of the chlorin e4 analogue.

[0250] To test for phototoxicity, cells incubated with chlorin e4 analogues (0–10 μM in DMSO) were incubated for 24 h with a medium change (as above) and then exposed to 50 mW / cm 2 The animals were exposed to a 660 nm laser (Invion) ​​or a light-emitting diode (LED) panel (Invion) ​​with a light power density of 15 J / cm2 for 5 min. 2 ). Laser and LED irradiation induce comparable responses in terms of phototoxicity. After activation, cells were cultured for an additional 24 hours. The medium was then replaced with fresh medium containing AlamarBlue and the survival rate of viable cells was assessed as above. Controls included cells treated with chlorin e4 analogues but not activated by laser light, cells not treated with chlorin e4 analogues but irradiated with laser light and an untreated control. All measurements were performed in quadruplicate.

[0251] Toxicity profile of chlorin e4 analogues The phototoxicity and intrinsic cytotoxicity (i.e., "dark toxicity") of chlorin e4 analogs were evaluated as previously using SKOV3 ovarian cancer cells. For comparison purposes, chlorin e4 analogs were compared to chlorin e4 disodium and talaporfin sodium, a clinically approved photosensitizer used in the photodynamic therapy of lung cancer. Phototoxicity IC90 and dark toxicity IC10 values ​​were calculated using a normalized response dose curve with a slope varying using the equation log[inhibitor]-vs. Hill slope (phototoxicity IC90), or Y=100 / (1+(IC10 / X)^Hill slope (dark toxicity IC10).

[0252] Phototoxicity and dark toxicity values ​​are shown in Table 1. The phototoxicity IC90 values ​​of all chlorin e4 analogs were in the nM range, with four compounds having IC90s below 5 nM (Table 1). These were significantly better than chlorin e4 disodium (IC90 21.32 μM) or talaporfin sodium (IC90 22.83 μM); in fact, the best performing compound (compound 6) achieved phototoxicity four orders of magnitude greater than talaporfin sodium. Thus, chlorin e4 analogs showed up to about 13,000-fold increased phototoxicity compared to talaporfin sodium, a clinically approved photosensitizer. Considerable variation was observed in the dark toxicity of the chlorin e4 analogs of the present invention (Table 1). However, the greater phototoxicity provided by the chlorin e4 analogs of the present invention is expected to offset the dark toxicity issue by requiring lower doses for use.

[0253] Therapeutic index of chlorin e4 analogues To evaluate the therapeutic potential of chlorin e4 analogs, the therapeutic index (TI) was calculated. The TI provides a quantitative measure that describes relative drug safety by comparing the drug concentration required for a desired effect with the concentration that results in undesired off-target toxicity. The TI was calculated using the phototoxicity IC90 versus the dark toxicity IC10.

[0254] The TI values ​​are shown in Table 1. Talaporfin sodium has a low therapeutic index (TI=0.49) and chlorin e4 disodium is only slightly better (TI=1.89), indicating that its relative cytotoxicity is low but its available therapeutic window is small. The chlorin e4 analogs of the present invention have a relatively significant improved TI with substantially greater phototoxicity (Table 1).

[0255] Therefore, the chlorin e4 analogs of the present invention have a desirable therapeutic index that is superior to that of clinically applied photosensitizers. Furthermore, the greater phototoxicity of the chlorin e4 analogs suggests the possibility of using significantly reduced doses in vivo. Therefore, the chlorin e4 analogs have a therapeutic profile suitable for clinical application. [Table 1]

[0256] It will be understood that the invention has been described above by way of example only. The examples are not intended to limit the scope of the invention. Various modifications and embodiments can be made without departing from the scope and spirit of the invention, which is defined solely by the following claims.

Claims

1. A compound of formula (I) or a complex of formula (II), 【Chemical 1】 or a pharmaceutically acceptable salt thereof, During the ceremony, -R 1 is -CH 2 OR 2 , -CH 2 SR 2 , -CH 2 S(O)R 2 , -CH 2 S (O) 2 R 2 , -CH 2 N (R 2 ) 2 , -R 2 , —C(O)—OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from: -R 2 is, independently of each other, -H, -C(O)R 4 -C(O)-OR 4 -C(O)-SR 4 -C(O)-N(R 4 ) 2 -C(S)-OR 4 -C(S)-SR 4 -C(S)-N(R 4 ) 2 -R α -H, -R β -R α -R β -R α -OH, -R α -OR β -R α -SH, -R α -SR β -R α -S(O)R β -R α -S(O) 2 R β -R α -NH 2 -R<000OO50>!-NH(R β ) -R α -N(R β ) 2 -R α -X, -R α -[N(R 5 ) 3 Y, -R α -[P(R 5 ) 3 Y, -R α -[R 8 Y, -R α -[N(R 5 ) 2 (R[[ID=8%)] 5’ )] -R α -[P(R 5 ) 2 (R 5’ )] or -R α -[R 8’ and is selected from; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O) 2 R β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ] Y, -R α -[P(R 5 ) 3 ] Y, -R α - [R 8 ] Y, -R α -[N(R 5 ) 2 (R 5’ ) ], -R α -[P(R 5 ) 2 (R 5’ ) or -R α - [R 8’ ] is selected from; -R α - are each independently C 1 ~C 42 alkylene groups, wherein said alkylene groups are optionally selected from one or more C 1 ~C 4 Alkyl, C 1 ~C 4 and one or more carbon atoms in the backbone of the alkylene group may be optionally substituted with O, S, NH, or NMe. may be substituted with a heteroatom or group independently selected from e; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or include a cyclic group, said hydrocarbyl group may be optionally substituted, and said hydrocarbyl group may optionally include one or more heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 ~C 6 heteroaryl, wherein said phenyl or C 5 ~C 6 Heteroaryl optionally includes one or more C 1 ~C 6 Alkyl, C 1 ~C 6 haloalkyl, —O(C 1 ~C 6 alkyl), —O(C 1 ~C 6 haloalkyl), halo, —CO 2 H, -CO 2 Z, -CO 2 NH 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be further substituted with groups; -R 5’ is C 1 ~C 4 Alkyl, C 1 ~C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 ~C 6 heteroaryl, each of which is —CO 2 - wherein said phenyl or C 5 ~C 6 The heteroaryl may optionally include one or more C 1 ~C 6 Alkyl, C 1 ~C 6 haloalkyl, —O(C 1 ~C 6 alkyl), —O(C 1 ~C 6 haloalkyl), halo, —CO 2 H, -CO 2 Z, -CO 2 NH 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be substituted with a group; -R 6 is -OR 2 , -N(R 2 ) 2 , -SR 2 , -S(O)R 2 , -S(O) 2 R 2 or -X; -R 7 is -C(O)-OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from: -R 8 optionally one or more C 1 ~C 6 Alkyl, C 1 ~C 6 haloalkyl, —O(C 1 ~C 6 alkyl), —O(C 1 ~C 6 haloalkyl), halo, —CO 2 H, -CO 2 Z, -CO 2 NH 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -substituted with a group -[NC 5 H 5 ] and -R 8’ is -CO 2 - and optionally one or more C 1 ~C 6 Alkyl, C 1 ~C 6 haloalkyl, —O(C 1 ~C 6 alkyl), —O(C 1 -C 6 haloalkyl), halo, —CO 2 H, -CO 2 Z, -CO 2 NH 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -[NC] further substituted with a group 5 H 5 ] and -R 9 is hydrogen or methyl; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation; the compound of formula (I) or the complex of formula (II), or a pharmaceutically acceptable salt thereof.

2. Each -R α - is independently C 1 ~C 6 2. The compound or complex of claim 1, wherein the alkylene is selected from the group consisting of alkylenes.

3. -R 2 , -R 3 and -R 4 At least one of the groups is -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O) 2 R β -R β A compound or complex according to any preceding claim, wherein is a saccharidiyl group.

4. -R β teeth, 【Chemistry 2】 4. The compound or complex of claim 3, wherein the saccharidiyl group is selected from:

5. The saccharidiyl group is 【Chemistry 3】 5. The compound or complex of claim 4, wherein:

6. -R β teeth, 【Chemistry 4】 is a saccharidiyl group selected from In the formula, -R 10 is C 1 ~C 4 4. The compound or complex of claim 3, wherein the alkyl is selected from the group consisting of alkyl, methyl ...

7. -R 10 The compound or complex of claim 6, wherein is methyl.

8. -R 1 is -C(O)-OR 3 and R 3 is -R β and -R β is C 1 ~C 4 10. A compound or complex according to any one of the preceding claims which is an alkyl group.

9. -R 1 is -C(O)-OR 3 , —C(O)—SR 3 or —C(O)—N(R 3 ) (R 3’ ) selected from -R 3 is -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O) 2 R β -R β is a saccharidiyl group, and —R 3’ is H or C 1 ~C 4 The compound or complex according to any one of claims 1 to 7, wherein the compound or complex is alkyl.

10. -R 6 is -OR 2 or -SR 2 -R 2 is -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O) 2 R β -R β 10. A compound or complex according to any one of the preceding claims, wherein is a saccharidiyl group.

11. -R 7 is -C(O)-OR 3 and -R 3 is C 1 ~C 4 10. A compound or complex according to any one of the preceding claims, wherein the compound or complex is alkyl.

12. -R 7 is -C(O)-OR 3 , —C(O)—SR 3 or —C(O)—N(R 3 ) (R 3’ ), and -R 3 is -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O) 2 R β -R β is a saccharidiyl group, and —R 3’ is H or C 1 ~C 4 The compound or complex according to any one of claims 1 to 10, which is alkyl.

13. The compound or the complex is 【Chemistry 5】 【change】 【change】 【change】 【change】 【change】 【change】 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.

14. 10. A compound or complex according to any one of the preceding claims for use in medicine.

15. 10. A compound or complex according to any one of the preceding claims for use in photodynamic therapy or cytoluminescent therapy.

16. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or vascular 10. A compound or complex according to any one of the preceding claims for use in the treatment of diseases characterised by areas of neoplasia; benign or malignant tumours; early stage cancers; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

17. 10. A compound or complex according to any one of the preceding claims for use in the treatment of diseases characterised by benign or malignant cellular hyperproliferation or by areas of neovascularisation.

18. 10. A compound or complex according to any one of the preceding claims for use in the treatment of benign or malignant tumors.

19. 10. A compound or complex according to any one of the preceding claims for use in the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

20. 10. A compound or complex according to any one of the preceding claims for use in photodynamic diagnosis.

21. 10. A compound or complex according to any one of the preceding claims, wherein the compound is adapted to be administered prior to the administration of radiation.

22. 22. The compound or complex of claim 21, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

23. 10. A pharmaceutical composition comprising a compound or complex according to any one of the preceding claims and a pharmaceutically acceptable carrier or diluent.

24. 24. The pharmaceutical composition of claim 23, further comprising polyvinylpyrrolidone.

25. 25. The pharmaceutical composition of claim 23 or 24, further comprising an immune checkpoint inhibitor.

26. 26. The pharmaceutical composition of claim 25, wherein the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.

27. The pharmaceutical composition according to any one of claims 23 to 26, for use in photodynamic therapy or cytoluminescence therapy.

28. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or vascular 28. The pharmaceutical composition of any one of claims 23 to 27 for use in treating a disease characterized by areas of neoplasia; a benign or malignant tumor; an early stage cancer; cervical dysplasia; a soft tissue sarcoma; a germ cell tumor; a retinoblastoma; age-related macular degeneration; a lymphoma; Hodgkin's lymphoma; head and neck cancer; an oral cancer; or a cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

29. A pharmaceutical composition according to any one of claims 23 to 28 for use in the treatment of diseases characterised by benign or malignant cellular hyperproliferation or by areas of neovascularisation.

30. A pharmaceutical composition according to any one of claims 23 to 29 for use in the treatment of benign or malignant tumors.

31. 31. The pharmaceutical composition of any one of claims 23 to 30 for use in the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

32. 25. The pharmaceutical composition of claim 23 or 24 for use in photodynamic diagnosis.

33. The pharmaceutical composition according to any one of claims 23 to 32, wherein the pharmaceutical composition is adapted for administration before the administration of radiation.

34. 34. The pharmaceutical composition of claim 33, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

35. 35. The pharmaceutical composition according to any one of claims 23 to 34, wherein the pharmaceutical composition is in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumoral, intraarticular, intraperitoneal, intracranial and epidural), transdermal, airway (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration.

36. 36. The pharmaceutical composition of claim 35, wherein the pharmaceutical composition is in a form suitable for oral or parenteral administration.

37. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; areas of benign or malignant cell hyperproliferation or angiogenesis 23. Use of a compound or complex according to any one of claims 1 to 22 in the manufacture of a medicament for the treatment of a disease characterized by: a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

38. 23. Use of a compound or complex according to any one of claims 1 to 22 in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy.

39. The phototherapeutic agent may be used to treat atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant 39. The use of claim 38 for the treatment of a disease characterized by areas of cellular hyperproliferation or angiogenesis; a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.

40. 40. The use according to any one of claims 37 to 39, wherein said medicament or said phototherapeutic agent is for the treatment of a disease characterized by benign or malignant cellular hyperproliferation or by areas of neovascularization.

41. The use according to any one of claims 37 to 40, wherein the medicament or phototherapeutic agent is for the treatment of benign or malignant tumors.

42. 42. The use of any one of claims 37 to 41, wherein the medicament or phototherapy agent is for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

43. Use of a compound or complex according to any one of claims 1 to 22 in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.

44. The use according to any one of claims 37 to 43, wherein the medicament, the phototherapeutic agent or the photodiagnostic agent is adapted for administration before the administration of radiation.

45. 45. The use according to claim 44, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

46. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors 23. A method of treating cancer of the following organs: early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas, said method comprising administering to a human or animal in need thereof a therapeutically effective amount of a compound or complex according to any one of claims 1 to 22.

47. 23. A method for photodynamic or cytoluminescent therapy of a disease in a human or animal, said method comprising administering to a human or animal in need thereof a therapeutically effective amount of a compound or complex according to any one of claims 1 to 22.

48. The human or animal disease may be atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or a disease characterized by areas of malignant cell hyperproliferation or angiogenesis; a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

49. 49. The method of any one of claims 46 to 48, wherein the human or animal disease is characterized by benign or malignant cellular hyperproliferation or by areas of neovascularization.

50. 50. The method according to any one of claims 46 to 49, wherein the human or animal disease is a benign or malignant tumor.

51. 51. The method of any one of claims 46 to 50, wherein the human or animal disease is early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.

52. 23. A method for the photodynamic diagnosis of disease in humans or animals, said method comprising administering to a human or animal a diagnostically effective amount of a compound or complex according to any one of claims 1 to 22.

53. 53. The method of any one of claims 46 to 52, wherein after administration of the compound or complex of any one of claims 1 to 22, the human or animal is subjected to irradiation.

54. 54. The method of claim 53, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.

55. (a) a compound or complex according to any one of claims 1 to 22; (b) a co-drug that is an immune checkpoint inhibitor.

56. 56. The pharmaceutical combination or kit of claim 55, wherein the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.

Citation Information

Patent Citations

  • Chlorin galactoside compounds as well as preparation method and application thereof

    CN107722077A

  • Dihydroporphin compound as well as preparation method and application thereof

    CN113461697A

  • Novel chlorin e4 derivative, pharmaceutically acceptable salt thereof, and preparation methods and application of novel chlorin e4 derivative and thepharmaceutically acceptable salt thereof

    CN113527319A

  • Chlorin derivative

    JP2012092024A

  • Chlorine derivatives useful in photodynamic therapy and diagnostics

    JP2016502999A